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 Lentiviral gene therapy has held great promise for treating a wide range of 
neurological disorders due to its ability to stably integrate into the genome of non-
dividing cells like neurons, in addition to dividing cells. The nervous system is a complex 
and highly heterogeneous system, and while a therapeutic intervention may have 
beneficial effects in one population of cells it may have severe side effects in another. For 
this reason, specific targeting of lentiviral vectors is crucial for their ultimate utility for 
research and clinical research use.  
 Two different approaches for focusing the targeting of lentiviral vectors were 
employed in these studies. The first method involved assessing the effects of vector 
production strategies on the resulting virus’s tropism both in vivo and in vitro. The 
changes in vector transduction were determined via flow cytometry on cells in culture 
and immunohistochemistry following brain injections. Results from these experiments 
suggest that while the production conditions do impact the vectors efficacy, there is not a 
distinct effect on their tropism.  
 A unique characteristic of retroviral and lentiviral vectors is their capacity for 
being pseudotyped, conferring a new tropism on the vector. Native tropisms are generally 
not specific beyond very broad cell types, which may not be sufficient for all 
applications. In this case, chimeric targeting molecules can provide an even more refined 
targeting profile compared to native pseudotypes.  
 The second approach utilizes novel chimeric glycoproteins made from nerve 
growth factor and the vesicular stomatitis virus glycoprotein. These chimeras are 
designed to pseudotype lentiviral vectors to target nociceptive sensory neurons for a 
variety of disorders. While these chimeras were successfully produced as protein, they 
were misfolded and sequestered in the endoplasmic reticulum and therefore unavailable 
to produce lentivirus.  
 While neither strategy was completely successful, they do provide interesting 
information for the design and creation of lentiviral vectors. This research shows that 
small differences in the steps followed as part of a lentivirus production protocol can 
greatly impact the resulting vectors efficacy. It also shows that while VSV has been used 
to create chimeric glycoproteins, not all targeting molecules are suitable for this purpose.
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Chapter One 
Introduction 
 
Overview 
Gene therapy has shown tremendous potential for the treatment of a multitude of 
disorders.  Unfortunately, except for modest clinical success in areas such as cancer gene 
therapy [1, 2] and treatment of primary immunodeficiency diseases such as severe 
combined immunodeficiency disease (SCID) [3, 4], this potential has gone largely 
unrealized.  The lack of translation from a promising potential therapy to an effective tool 
in the physician’s arsenal can be attributed to a number of reasons; expression levels and 
duration; immune reaction to the vector/transgene; transgene impact on surrounding 
genes; physiological context, including targeting and regulation; long term (1, 5, 10 or 50 
years) follow up. These considerations have been reviewed in many sources over the 
years [5, 6]. The same questions must be addressed during the development of any 
pharmacological treatment, only with the added stigma and ethical concerns associated 
with genetic engineering due to the higher public awareness of notable gene therapy 
failures [7-10].  
The overall goal of the research outlined in the following chapters was to add to 
the knowledge base associated with the targeting of lentiviral vectors. Specifically, these 
studies examined how production protocols affect the targeting and efficacy of lentiviral 
vectors, both in vitro and in vivo. They also assessed whether novel chimeras between 
nerve growth factor and the vesicular stomatitis virus glycoprotein can be used to 
pseudotype and specifically target lentiviral vectors. 
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History of Gene Transduction 
 The concept of manipulating an organism’s genetics is not a new one. Humankind 
has been intentionally (and unintentionally) altering the traits of the plants and animals 
around us for our own benefit for thousands of years. We were genetically engineering 
different organisms, but without an idea of what we were actually manipulating to induce 
phenotypic changes seen. In the 1860’s Haeckel postulated that the nucleus was the 
source of “factors” responsible for heredity, and the work of several other scientists 
showed that heredity had a molecular basis. Nucleic acid was then discovered in the 
1870’s by Friedrich Miescher [11], and the possibility that it contained the heritable 
information of the cell was briefly considered but discarded as unlikely. The dawn of the 
twentieth century saw the rediscovery of the work of Mendel, and the concept formally 
linking heredity of traits with “genes,” though their physical composition was still 
unknown.  
 Around the same time several researchers, proposing that DNA did not have 
sufficient ability to encode the information required for diversity of life as the four bases 
had to exist in equimolar concentrations, forwarded the “tertranucleotide hypothesis”. 
The ability of DNA to convey information remained unknown, and considered unlikely, 
until Avery et al [12] used purified DNA to transform pneumococcus bacteria from the 
rough (R) to smooth (S) strains in a classical set of experiments. The latter part of the 
1940’s also saw Chargaff and colleagues determine that while the ratio of A/T and G/C 
were very close to one, the other ratios could vary greatly between organisms, further 
solidifying the potential for DNA to encode heritable information [13].  
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In the 1950s it was shown that viral infection of bacteria by bacteriophages 
resulted in the phages DNA entering the cell [14]. Throughout the 1950’s and 1960’s 
experiments were done showing labeled DNA could be taken up by eukaryotic cells [15, 
16].  These experiments did not generate any change in cell traits, unlike the bacterial 
experiments performed by Avery.  Following these simple uptake experiments, it was 
reported that DNA from healthy human cells could be used to rescue β-Globin expression 
in bone marrow cells from sickle cell patients. Subsequently, Szybalska and Szybalski 
[17] published the development of hypoxanthine-guanine phosphoribosyl transferase 
(HPRT) deficient cells and media (HAT) that would enable selection for cells whose 
HPRT expression had been rescued by introduction of HPRT+ DNA. These experiments 
also showed that CaCl2 in phosphate buffer aided in transfection, which ultimately led to 
others defining the calcium phosphate transfection protocol.  
 Even before it was determined that viruses could encapsidate “foreign” or host 
DNA [18] it was proposed that viruses could be used to deliver genes [19]. Qasba et al 
[20] reported the first heterologous viral transfer of foreign genetic material by 
transferring mouse DNA to human cells. At this stage however, viral gene delivery was 
simply that – delivery of some genetic material via a virus, and was not limited to any 
specific genes nor did it result in any detectable physical outcome. The development of 
recombinant DNA technology and improvement of molecular cloning techniques in the 
1970’s provided viral gene therapy the tools to begin producing truly effective and useful 
gene delivery vehicles. Successful delivery and expression of non-viral genes did not 
occur until 1979 when Berg and colleagues used SV40 to deliver rabbit β-Globin [21]. 
These advances also allowed the expansion of the field beyond using DNA viruses (such 
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as SV40, adenoviruses and Herpes Simplex virus – though all have continued to be used 
and studied to various degrees) into RNA viruses like retroviruses. 
 
Retroviral Vectors 
 Retroviruses are a large family of enveloped viruses with a single-stranded RNA 
genome. Virions contain two copies of this genome, which can run between seven and 
thirteen kilobases in length, depending on the viral species. There are two main retroviral 
subfamilies: Spumaretrovirinae (which contain only the Spumavirus genus) and 
Orthoretrovirinae (that contains the alpha through epsilonretrovirus and lentivirus 
genera). In addition to these exogenous members of the retroviral family, there are also 
endogenous retroviruses that are often categorized based upon their relatedness to 
exogenous genera. 
 Generally speaking, retrovirus genomes have three open-reading frames (ORFs): 
1). The group specific antigen (gag), which encodes the viral structural proteins. 2). 
Polymerase (pol), which encodes the viral enzymes (reverse transcriptase, protease and 
integrase). 3). Envelope (env), which encodes the surface/coat protein. Some of the more 
complex family members may also encode additional gene products as splice variants of 
the standard reading frames (Fig 1-1).  
 The retroviral infection cycle begins with a mature virion binding to its cellular 
receptor. In the case of most retroviruses this binding event results in pH-independent 
conformational changes, which lead to fusion between the viral and cellular membranes 
[22, 23]. Research has shown that other retroviral family members such as ASLV and 
amphotropic and ecotropic murine leukemia viruses may need the involvement of the 
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endocytic pathway, but do not exhibit classical pH dependent fusion [24-27]. Following 
membrane fusion the capsid is released into the host cell and undergoes reorganization 
before reverse transcription converts the RNA genome into double-stranded DNA. The 
DNA copies of the viral genome begin trafficking to the host cell nucleus, but cannot 
penetrate the intact nuclear membrane [28] and therefore cannot lead to productive 
infection or integration [29, 30]. The notable exceptions to this are the lentivirus and 
spumavirus genera, which through interactions with cellular machinery can enter an 
intact nucleus. Once able to interact with the host cell genome, integration takes place. 
Some retroviruses exhibit a preference for regions with which to integrate, but it is far 
from uniform. Integrated provirus is now free to be transcribed into RNA, both full-
length viral genomes and the splice variants needed for protein production. This RNA is 
exported from the nucleus into the cytoplasm where it can be packaged or translated into 
protein. Viral proteins assemble at the cell surface and RNA is packaged. Virus is able to 
bud from the cell, though some additional proteolytic processing can occur to create 
mature virions. 
  One of the first retroviruses described was the alpharetrovirus, Rous Sarcoma 
virus (RSV) in 1910. Due to the early descriptions of RSV and avian sarcoma leukosis 
virus (ASLV), much of the early research into retroviruses focused on alpharetroviruses. 
In fact, members of this genus were used in studies discovering the ability of retroviruses 
to integrate in the host cell genome [31] and the existence of the viral reverse 
transcriptase enzyme [32, 33]. The largest group of retroviruses is the gammaretroviral 
genus, and members of this group provided the basis for most of the retroviral gene 
therapy vectors utilized in the 1980’s and 1990’s.  
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In the early 1980’s, recognizing their ability to stably integrate into the host cell 
genome, a number of groups began investigating the possibility of using retroviruses to 
deliver non-viral genes. While the potential for curing human diseases was in mind, 
researchers were also searching for more efficient means of gene transfer as a molecular 
biology tool. Early attempts utilized several different retroviruses to create these vectors, 
including: Spleen Necrosis Virus [34], Harvey Murine Sarcoma Virus [35] and Murine 
Leukemia Virus [36]. Despite utilizing different vectors, each of these early studies 
required the complement of deleted genes via infection of producer cells with a wild-type 
retrovirus, resulting in a contamination of gene transfer vector with wild-type virus. 
When performing in vitro experiments this contamination may not detrimentally affect 
experiments, but more complex in vitro and in vivo experiments would require 
elimination of any wild-type virus.  Previously, it was observed that specific mutant RSV 
particles could be generated without the packaging of their RNA genomes [37]. This 
observation led to the construction of a helper-free production system for retroviral 
vectors [38, 39]. 
 Following the successful transfers of Herpes Simplex virus Thymidine Kinase to 
Thymidine Kinase deficient cell lines, researchers attempted to correct a human genetic 
disease in vitro by providing a replacement functional gene via retroviral delivery. In 
1983, studies by Miller et al [40] showed that the Human Hypoxanthine Phosphoribosyl 
Transferase could be expressed in both rat and human cells deficient in the gene. 
Subsequently, a retroviral vector was used to deliver the Adenosine Deaminase (ADA) 
gene to primary lymphocytes from ADA-deficient Severe Combined Immunodeficiency 
Syndrome patients [41].  
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 During the 1980’s retroviral vectors were used to deliver ADA to lymphoid and 
hematopoetic stem cells with the intention of reimplanting them into the donor, termed 
exogenous gene therapy. Also, studies (and an eventual clinical trial) were successful in 
rescuing immune function in an Adenosine Deaminase deficient Severe Combined 
Immunodeficiency patient [4]. A clinical trial to treat X-linked SCIDS reported 
successful treatment of several patients [42]. Problems with the trial were associated with 
the induction of aberrant gene expression around some of the gene integration sites, 
which resulted in a subset of the patients developing leukemia [9, 10]. While a number of 
trials have achieved modest successes clinically, due to public perception retroviral 
vectors are often looked upon poorly and their usage in clinical protocols is shrinking 
[43]. However, these vectors have become widely used tools in biology to study a host of 
conditions and processes. 
 One of the shortcomings of using retroviral vectors is they are unable to 
productively transduce cells which are not actively dividing [44]. This limits their utility 
in gene therapy of the nervous system as well as muscle, stem cells (due to the cells 
having to be induced to divide, in order for transduction to occur) and a number of 
additional cell types. For this reasons many early studies in the nervous system utilized 
adenoviral or herpes viral vectors. 
 
Lentiviral Biology 
 As the use of gammaretroviral vectors was increasing through the 1980’s and 
early 1990’s, a new group of viruses within the retroviral family was defined. Acquired 
Immunodeficiency Syndrome (AIDs) was first characterized in the early 1980’s via the 
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documentation of a population of homesexual men and intravenous drug users presenting 
with fungal pneumonia and muscosal candidiasis, as well as, a marked acquired defect in 
T-lymphocytes [45, 46]. Initial studies classified the causative agent as Human T-cell 
Leukemia virus (HTLV) or a separate but related retrovirus [47-50]. Ultimately, it was 
determined that the etiological agent of AIDS was a previously unclassified virus 
(Human Immunodeficiency Virus), that while related to HTLV, comprised a new and 
separate genus (Lentivirus) of retroviruses.  
 Discovery of HIV was followed by the description or reclassification of related 
viruses of monkeys/apes (SIV) [51, 52], pigs (BIV), cats (FIV), horses (EIAV) and goats 
(CAEV) among others, which led to the creation of the “Lentivirus” subdivision of 
retroviruses.  
 Lentiviruses are a genus of enveloped, positive sense single-stranded RNA 
viruses with a genome of 9-12kb [53-55] (Fig. 1-1). The genome of HIV exhibits a 
structure very similar to that seen in other retroviruses. The integrated provirus has 
flanking long terminal repeats (LTRs), which act as important sites for transcriptional 
initiation and polyadenylation. The first of three main open reading frames (ORFs) 
encodes for the gag proteins (p17 matrix, p24 capsid, p7 nucleocapsid and p6), which 
must be cleaved by the viral protease into individual proteins. The gag components create 
the internal structure of the virus, envelope interaction, membrane anchoring and RNA 
binding. A frameshift during translation results in the pol proteins (protease, reverse 
transcriptase and integrase). The viral protease aids in the maturation of viral proteins, 
reverse transcriptase converts the viral RNA genome into DNA and integrase inserts the 
DNA into the host cell genome. The third major open reading frame belongs to the 
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envelope gene (gp160), which must be processed into gp120 (surface) and gp41 
(transmembrane/fusion). As the surface/coat protein, it mediates binding to the virus’s 
cellular receptors (CD4 and secondary receptors), and exists as a homotrimer on the 
virions surface.  
 There are a number of additional proteins produced from the frameshifting and 
splicing of the viral genome. Two of these proteins are absolutely required for full wild-
type viral infectivity: TAT is an essential regulatory factor that initiates 
transcription/elongation from the LTR. The second is Rev, a factor required for efficient 
export and stability of viral messenger RNA (mRNA). The remaining four accessory 
proteins, while important to viral function, can be dispensed with in lentiviral gene 
therapy vectors without significant detriment. These four proteins are: viral infectivity 
factor (VIF), viral protein R (VPR)/viral protein X (VPX), viral protein U (VPU) and 
NEF. Each of these proteins has multiple proposed and attributed functions.  
 The life cycle of lentiviruses is very similar to that of other retroviruses (Fig. 1-2). 
Mature virus binds to its cellular receptor(s) and this binding initiates pH independent 
[56] conformational changes, leading to the fusion of the viral and cellular membranes 
and capsid release [57]. Once reverse transcribed, the DNA copy of the viral genome is 
able to enter the nucleus of nondividing cells [58, 59]. It is still somewhat controversial 
as to what mediates this ability, and it has been attributed to many of the molecules 
encoded by HIV, as well as several cellular factors. The successful use of lentiviral gene 
therapy vectors to transduce nondividing cells would seem to eliminate the accessory 
genes as they are not present.  
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Lentiviral gene therapy has held great promise for treating a wide range of 
neurological disorders due to its ability to stably integrate into the genome of non-
dividing cells like neurons [60] in addition to dividing cells.  Gene delivery vehicles 
based on lentiviruses are non-immunogenic and provide an efficient means of delivering 
long-term gene expression to multiple organ systems [61]. 
 
Lentiviral Gene Therapy 
 Vectors based on γ-retroviral vectors (such as MLV and GaLV) had been shown 
to have many qualities desirable for gene therapy, but due to their inability to transduce 
non-dividing cells the scope of their utility was limited. HIV-1 and other lentiviruses 
were known to be able to infect non-dividing (or cell cycle arrested) cells [58, 62], and 
could still maintain many of the attractive characteristics associated with γ-retroviral 
vectors. In 1996, Naldini et al [63] described the construction of a vector system on HIV-
1. This early system deleted the wild-type HIV-1 envelope (GP160) and the packaging 
signals in the vector, and also replaced the long terminal repeats with the 
cytomegalovirus immediate early promoter and insulin poly-A (5’ and 3’ respectively). 
This vector utilized separate plasmids; the vector containing gag/pol, one encoding a 
heterologous envelope and a gene expression plasmid containing the packaging and other 
cis acting sequences required to produce functional virus (Fig. 1-3a). Lentiviral vectors of 
this generation successfully transduced neurons in vivo and other nondividing cells in 
vitro. This expression could be sustained for several months after viral injection and did 
not result in detectable immune response [60].  
	  11	  
 Due to concerns over this vector being based on a serious human disease agent, 
efforts were made to both improve the potential safety of HIV-1 based vectors and begin 
creating vectors based on non-human lentiviruses. As research progressed on HIV-1 
biology, better understanding of several of its accessory genes showed that while 
important to productive wild-type viral infection in vivo they were not required. The 
second generation of HIV-1 based vectors deleted Vif, Vpr, Vpu and Nef [64, 65] and 
retained their ability to transduce non-dividing cells (Fig. 1-3b). These deletions removed 
unnecessary genes, which have the potential for cytotoxic and immunological side 
effects, and further decreased the chances for homologous recombination by removing 
sequence homology. The next major safety modification of lentiviral vectors created 
“self-inactivating” (SIN) vectors that have the viral enhancer/promoter sequences deleted 
[66]. This modification would prevent the mobilization of replication-competent virus 
from transfected cells and transactivation of genes surrounding the integration site. 
Additionally a replacement of the U3 region of the 5’ LTR with a heterologous 
promoter/enhancer removes TAT-dependent transcription of the vector genomic RNA. 
This modification scheme is similar to that seen a decade previous in the construction of 
SIN γ-retroviral vectors [67, 68]. 
 The third generation of vectors moves the Rev regulatory gene from the gag/pol 
plasmid to its own plasmid [69] (Fig. 1-3c). This relocation does lower the packaging 
activity to a degree, but provides additional safety. As a viral mRNA export/stability 
agent (such as Rev) is required to efficiently produce vector, it cannot be removed 
completely. However, this function can be supplied by replacing Rev with heterologous 
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transport elements of other viruses in the packaging plasmid [70-73], though they are not 
as effective as the native Rev.  
 Codon optimization of the viral gag/pol gene by inactivating inhibitory sequences 
in the genes can alleviate some of this reduced mRNA transport and further reduces 
homology between the sequences of gag/pol and the encapsidation (Δψ)/cPPT sequences 
of the gene transfer plasmid [74, 75]. Most current HIV-1 based vectors are third 
generation or codon-optimized third generation, and all of the vectors utilized in the 
studies in this dissertation are third generation SIN vectors that still make use of HIV’s 
Rev to improve mRNA export.  
 In parallel with these safety advances in HIV-1 based vectors, vectors based on 
other members of the lentiviral family were also developed: HIV-2 [76], SIV [77], FIV 
[78], BIV [79], EIAV [80] and CAEV [81, 82]. Similar safety modifications were also 
made in these vectors [83-87], though the use of these vectors is still not as widespread as 
with HIV-1 based vectors. 
 A major concern with gammaretroviral vectors, which ultimately led to the 
shutdown of an early clinical trial, was its potential to transactivate production of host 
genes surrounding the vector’s integration site [9, 10]. In the aforementioned studies the 
aberrant activation of LMO2 expression in a portion of the patients ultimately led to them 
developing leukemia. Subsequently, this was determined to be due to a confluence of 
circumstances, and theorized to not likely be a regular occurrence. Regardless, lentiviral 
vectors (and later generations of gammaretroviral vectors) have attempted to avoid this 
problem through the creation of the previously mentioned SIN vectors and several 
additional modifications such as chromatin insulators [88-91] and targeted insertion 
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(reviewed in [92]), to name a few. Trials with gamaretroviral vectors without these 
modifications have been allowed to continue on a case-by-case basis however.  
 
Targeting of Enveloped Vectors 
 Even when the field was in its infancy, it was recognized that to be effective gene 
therapy would have to be targeted. In a review from 1972 on the prospects for gene 
therapy, Friedmann and Roblin [93] stated “Methods would have to be developed to 
deliver the exogenous DNA to the appropriate “target tissue,” and to confine its action 
solely to that tissue.” Much of the early gene therapy experiments were based on in vitro 
or ex vivo transduction, so this was not a major concern. However, as gene therapy 
advanced into more and more in vivo studies targeting became an area of intense interest. 
The most straightforward approach to constrain the actions of a genetic therapy is purely 
mechanical in nature: administer the vector via localized injection. This can be effective 
when targeting more homogeneous tissues or when targeting preference is between 
highly disparate locations. This is not as effective in more heterogeneous targets though, 
and other methods must be employed. 
 One method for achieving this is through limiting where the transgene can be 
expressed transcriptionally. This can be accomplished through the incorporation of cell or 
tissue specific promoters into the vector. In the nervous system a number of different 
promoters have been explored as ways to improve targeting of neurons [94, 95]. 
Generally speaking, these promoters are associated with a neuronal specific or enriched 
gene (such as AMPA glutamate receptor subunit 2 or synapsin I). While neuron specific 
promoters do increase the tropism for neurons, sometimes approaching 100% - depending 
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on the brain region and promoter, the expression levels are often very low when 
compared to non-specific promoters. To counter this, hybrid promoters which couple the 
neuron specific promoters to a viral enhancer (such as the CMV enhancer with the neuron 
specific enolase promoter), have been studied. In this case, increased expression levels 
must be balanced with the loss of some specificity.  
 The second main method is to limit which cells can be infected by the viral 
vector. This is accomplished through pseudotyping an enveloped viruses core with the 
envelope protein of another viral species, conferring its tropism on the resulting vector. 
This had been reported as early as 1982, with the combining of the phenotypical traits of 
the vesicular stomatitis and vaccinia viruses [96]. Early research into retroviral vectors 
likely did this unintentionally by rescuing their gene delivery vehicles with wild-type 
retroviruses of other species. One of the first intentional instances of pseudotyping was 
published in 1985 when Miller et al [97] replaced the native coat protein of their vector 
with that of the amphotropic MLV there by introducing a broader tropism on the vector. 
Studies on cells infected with HIV and a second virus had shown that virions were 
produced with altered host ranges and heterogeneous phenotypes [98-100]. These studies 
served to truly open up the field of targeting of enveloped viral vectors. 
 While most surface proteins from enveloped viruses can be used to pseudotype 
retroviral and lentiviral vectors, some result in lowered efficiency or are not compatible at 
all. Notably, the glycoproteins from the gibbon ape leukemia virus (GALV), cat 
endogeneous retrovirus (RD114) and similar viruses do no effectively pseudotype 
lentiviral vectors. However, if the cytoplasmic tails of these glycoproteins are replaced by 
the tail from the amphotropic MLV glycoprotein, both of these become highly effective 
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lentiviral pseudotypes [101-103]. This would seem to support the theory that as long as a 
glycoprotein is present in sufficient quantities in the proper location, and there aren’t any 
steric issues between it and the viral core then it can pseudotype the viral particle.  
 For lentiviral vectors the default pseudotype has been the glycoprotein from the 
vesicular stomatitis virus (VSVG). This protein has the benefit of conferring a broad 
tropism (however, its receptor is still unclear) and a high degree of stability [63, 104], 
though it is susceptible to serum complement in humans. A wide range of pseudotypes 
for lentiviral vectors have been investigated and are reviewed in [105].  
 To improve neuronal tropism some of the most promising pseudotypes utilize 
glycoproteins from different strains of Rabies and rabies-related viruses. The use of 
glycoproteins from Rabies virus (and the related Mokola virus) to pseudotype vectors 
was first reported in 1998 by Mochizuki [106]. Both showed a neuronal preference, 
although a strain dependent difference in transduction efficiency with Mokola 
glycoprotein pseudotypes has been observed [107, 108]. In addition to its neurotropism, 
Rabies pseudotypes allow retrograde (and potentially transynaptic) transport of vectors, 
providing the option of peripheral administration [109]. Mokola pseudotypes also allow 
retrograde transport when pseudotyped onto EIAV vectors [110-112], though the papers 
by Desmaris and Watson showed some conflicting results of this ability in HIV1 vectors. 
 Not all nervous system gene therapy is focused on transduction of neurons. The 
glycoprotein from Lymphocytic Choriomeningitis virus (an arena virus) has been shown 
to have a preference from astrocytes and gliomas [113-115]. Additionally, when 
pseudotyped with the glycoprotein from the Ross River virus, FIV vectors had a distinct 
glial tropism [116]. 
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  There are a number of different strategies that are available to modify viral 
glycoproteins that allow targeting to be directed to even more defined populations of 
cells. Some of these strategies will be discussed in more detail in the introduction of 
Chapter Three.  
 
Aims of this Dissertation Research 
 Targeting through the use of cell-type specific promoters and viral pseudotypes 
are not the only methods that can be employed. Pseudotypes can be modified to more 
finely tune their targeting, or grossly modified to create entirely novel tropisms. 
Additionally, there has been some evidence that production strategies can have an effect 
on the vector’s targeting. The overall goal of the research outlined in the following 
chapters is to add to the knowledge base on the targeting of lentiviral vectors. 
Specifically, the aims are: 
 
1). To determine how production protocols effect the targeting and efficacy of lentiviral 
vectors, both in vitro and in vivo.  
2). To determine whether novel chimera’s between nerve growth factor and the vesicular 
stomatitis virus glycoprotein can be used to pseudotype and target lentiviral vectors. 
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Chapter Two 
 
Introduction 
 The protocol for the production of lentiviral vectors has followed a rather standard 
time course of harvests either at 40 and/or 64 hrs following transfection using 293FT or 
293T cells [117]. Generally speaking, the choice in harvest length [118] and cell type 
[119] was based around the goal of maximizing titers. Until recently [120], the effect of 
harvesting at these different time points on the vector functionality has not been explored 
in detail. Much of the research into lentiviral vector production has been centered on the 
following areas: the desire to minimize HIV sequences in the gene of interest plasmid as 
well as to separate the required HIV genes onto distinct plasmids [121]. The addition of 
“helper sequences” to the expression cassette in order to increase expression [122-124], 
modify insertional capabilities [125] or prevent activation of downstream genes [126, 
127]. The ability of heterologous glycoproteins to effectively pseudotype the lentiviral 
vector [105]. And, the most effective methods to improve titers and vector quality via 
transfection [128] or concentration [129].  
 Production protocols are generally chosen in order to maximize titers and minimize 
in vivo immunogenicity. Beyond measuring effective titer in a single generic cell line, 
little is done to compare the ability of these lentiviral vectors, produced under different 
conditions, to transduce multiple cell populations in vitro or in vivo. The studies here 
show that the cell lines used and the length of time before harvesting do affect the vectors 
ability to transduce various cell types, both in vivo and in vitro. The successful 
application of lentiviral vectors to nervous system studies in the future will require the 
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use of an appropriate production protocol. 
 
Viral Production 
There are many different protocols for the production of lentiviral vectors, but all 
agree on using producer cells derived from the Human Embryonic Kidney (HEK 293) 
cell line. However, specific protocols for large-scale production [130-132] and those 
using stably transfected producer lines [133-136] often utilize more specialized 
derivatives of HEK cells.  
HEK 293T and HEK 293FT are the standard producer cells for transient 
transfection based production of lentiviruses and are derived from the same original cells 
(HEK 293 [137]), and both have been transduced with the SV40 large T-antigen. The 
main difference being 293FT’s were derived from a faster growing clonal population of 
the original 293 cells. While these differences would appear inconsequential, growth rate 
and metabolic demands can have a considerable impact on the pH and composition of the 
growth media, which ultimately influence the efficacy and tropism [120] of vectors 
produced.  
Harvest length also can vary between protocols with the resulting vector 
containing supernatant being harvested either 40-48 hrs [138] or 60-72 hrs [66, 139, 140] 
post-transfection. Little work has been done to determine the effects of these different 
harvest lengths, beyond the changes of their apparent titers [118] in a limited cell 
population. In the studies outlined in this dissertation the contribution of harvest length 
and producer cell line to viral efficacy/tropism in vitro and in vivo are investigated.  
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pH Effects on Vesicular Stomatitis Virus Glycoprotein 
 Virions bind to their receptor and are endocytosed, where they traffic to low pH 
endosomes. Exposure to low pH causes a reversible conformational change in VSVG’s 
structure, as indicated by similar studies in the related viral glycoprotein from Rabies 
virus [141]. This three-dimensional conformation change can induce the fusion of the 
viral envelope with the cellular membrane and subsequent release of the nucleocapsid 
[142]. Low pH pretreatment has been shown to cause migration of the glycoprotein on 
the surface of VSV particles [143], resulting in individual virus particle aggregation 
[144], potentially due to exposure of hydrophobic domains.  There is a threshold for this 
aggregation and at moderately low pHs it doesn’t occur at significant levels and the virus 
is, in fact, activated for fusion. 
 Based on published research, there are indications that vector production 
conditions can have a significant effect on the characteristics of the resulting vector. The 
goal of the subsequent experiments is to determine if harvest length and/or producer cell 
line can alter the functionality of lentiviral vectors. Functionality in these studies is 
defined by changes in two measures: 1). Tropism, defined here has changes in 
transduction of one population of cells compared to transduction of another. 2). Efficacy, 
which is utilized here as the overall transduction efficiency of a particular vector.  
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Materials & Methods 
 
Lentiviral vector production 
 General lentiviral vector production protocol was based on protocols previously 
described [117]. In brief, both 293FT and 293T cells were maintained in Dulbecco’s 
modified Eagles medium (DMEM), which was supplemented with 10% newborn calf 
serum (NCS) (GIBCO; Carlsbad, CA), 100 units/ml penicillin, 100 µg/ml streptomycin 
and 0.5 µg/ml gentimycin in a 37°C incubator with 5% CO2. For virus production, cells 
used had gone through 10-15 passages. Cells were plated into 10-cm dishes, at a 
confluency of approximately 30%, 24 hrs before transfection. Upon reaching the desired 
confluency (approximately 60% at time of transfection) media was changed to DMEM + 
10% NCS without antibiotics and the cells allowed to recover for 2-3 hrs. The required 
plasmids were mixed at the ratio of 3.3 µg pLp-VSVG; 4.9 µg pMBL (gag/pol); 2.3 µg 
Rev; 3.5 µg pBOB-GFP per dish of cells, and cotransfected using calcium-phosphate 
precipitation [145]. After transfection, cells were moved to a 37°C incubator with 3% 
CO2. The culture media was changed 16 hrs after transfection to the harvest media of 
DMEM-HEPES with 10%NCS, 100 units/ml penicillin, 100 µg/ml streptomycin and 2 
mM l-glutamine. Cells were then allowed to produce virus for 24 or 48 hrs after media 
change (depending on the desired harvest length), before virus containing supernatants 
were harvested (Fig. 2-1a). A single lot of calf serum was used in the production of all of 
the vectors for these studies.  
 For all harvest lengths, the appropriate viral supernatants were pooled and 
immediately centrifuged at 500xg for 5 minutes to remove any contaminating cellular 
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debris and passed through a 0.45 µM vacuum filter. The resulting supernatants were then 
centrifuged through a 4 ml 20% sucrose cushion at 25,900 rpm, 4°C for 2 hrs with a SW 
32ti swinging bucket rotor. Viral pellets were resuspended in 20µl (per tube) 20 mM Tris 
pH 7.4 with 100 mM sodium chloride, 10 mg/ml sucrose, 10 mg/ml mannitol and 2 
mg/ml rat albumin (TSSM) then stored at -80°C.  
 Approximate titers were determined via standard p24 ELISA (Aalto BioReagents; 
Dublin, Ireland). In brief, equal volumes of each of the vector preparations were mixed 
with Empigen Zwitterionic detergent (Fluka; St. Louis, Mo) and incubated for 30 minutes 
at 56°C. These vector preparations and p24 protein standards (of known concentration) 
were then serially diluted and added in duplicate to 96-well plate coated in anti-p24 
antibody (Aalto BioReagents). Plates were incubated at room temperature for 2-3 hrs, 
washed and blocked with 2% milk in Tris-buffered saline (TBS) at room temperature for 
1 hr. Alkaline Phosphatase conjugated anti-p24 antibody (Aalto BioReagents) is diluted 
1:25 in 20% sheep serum with 0.05% Tween-20 in TBS and added to plate, for 30 
minutes at room temperature. To determine the quantities of p24 bound the AMPAK 
ELISA visualization kit (Oxoid; Cambridge, UK) was used. The subsequent color change 
was quantified via 492nm light absorption with a plate reader. p24 protein concentration 
was then determined by comparing the vectors OD492 value(s) with those of the standard 
curve’s. 
 
pH assessment 
 In part of assaying the viral production, additional batches of virus were produced 
in parallel, as described in the previous section. Instead of beginning the concentration 
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process, media was collected and the pH immediately determined. For each cell line and 
harvest length, the pH from three separate batches was recorded and an average of these 
numbers reported along with SEM. Significant difference between harvest media pH, due 
to harvest length and/or producer cell line, was determined via two-way ANOVA; 
p<0.005 was considered significant.  
 
Cell culture and in vitro transduction 
 
Tissue culture cell lines 
HEK 293FT cells were cultured in DMEM supplemented with 10% NCS, 100 
units/ml penicillin, 100 µg/ml streptomycin and 0.5 µg/ml gentimycin.  U373 
astrocytoma and SH SY5Y neuroblastoma cells were both cultured in DMEM 
supplemented with 10% NCS, 100 units/ml penicillin and 100 µg/ml streptomycin. PC12 
rat pheochromocytoma cells were cultured in DMEM supplemented with 10% NCS, 5% 
horse serum (Gibco), 100 units/ml penicillin and 100 µg/ml streptomycin.  
Cell lines were plated into duplicate wells of 12-well plates at a concentration of 
2x105 cells per well. The various vector preparations were added at an approximate 
multiplicity of infection (MOI) of 100, 24 hrs after plating. Culture media was changed at 
16 hrs after the addition of virus. GFP expression was allowed to continue for 72 hrs.  
 
Rat astrocyte cultures 
Primary astrocytes were harvested from p1-2 newborn pup cortices as previously 
described [146]. Briefly, cerebral cortices were dissociated in 0.25% Trypsin/EDTA, 
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centrifuged and resuspended in DMEM with 10% fetal bovine serum, 100 units/ml 
penicillin and 100 µg/ml streptomycin. Astrocytes were plated into a T-75 flask and the 
media changed every 2-3 days. After approximately one week, contaminating cells are 
dislodged by gentle shaking and discarded. For transduction and counting, primary 
astrocytes were handled in the same manner as the tissue culture cell lines. 
 
Rat dorsal root ganglion cultures 
Rat DRG cultures were harvested from p1-2 newborn rat pups as previously 
described [147]. The ventral aspect of the vertebral column was carefully removed, 
exposing the spinal cord and DRG’s. Whole DRG’s were removed using forceps and 
placed in cold Hank’s buffered saline solution (HBSS). The ganglia were then digested 
with 0.25% collagenase, 0.25% trypsin and then triturated. Cells were preplated onto 
uncoated tissue culture dishes in DMEM with 10% NCS, 100 units/ml penicillin and 100 
µg/ml streptomycin and the non-neuronal cells allowed to attach for 2-3 hrs. Neurons 
were detached by gentle shaking and counted, followed by plating onto matrigel coated 
12-well plates.  DRG neurons were cultured in DMEM with B27 (GIBCO), N2 (GIBCO) 
and 50ng/ml Nerve Growth Factor (Invitrogen; Carlsbad, CA).  
Two days following plating, viruses were added at a MOI of 100 to triplicate 
wells. The culture media was changed to fresh culture media 16 hrs later and then GFP 
expression was allowed to continue for a total of 72 hrs.  
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Dorsal root ganglion culture immunocytochemistry 
Dorsal root ganglion cultures were fixed with 4% paraformaldehyde, and 
permeabilized with 0.1% Triton X-100 (Sigma; St. Louis, MO). Blocking was performed 
with 4% goat serum, and then incubated with the primary antibody, mouse anti-NeuN 
(Millipore; Billerica, MA) diluted 1:250. Goat anti-mouse IgG conjugated to Texas Red 
(Jackson ImmunoResearch; West Grove, PA) at a dilution of 1:250 was used for the 
secondary antibody. The number of NeuN positive cells from 5 random fields from three 
separate trials were counted manually from each, the subset of these cells that were GFP 
positive, in addition, to NeuN positive were also counted. For each cell line and harvest 
length, the percent transduction from the three separate trials was recorded and an 
average of these numbers reported along with SEM. Significant difference in vector 
functionality, due to harvest length and/or producer cell line, was determined via two-
way ANOVA; p<0.05 was considered significant. 
 
Direct effect of pH on transduction efficiency 
 Lentiviral vector encoding GFP was produced in 293T cells and harvested after 
64 hrs as indicated previously. HEK 293FT cells were plated at 2x105 cells/well into a 
12-well plate and allowed to attach for 24 hrs. Equal titers of vector (MOI=10) were then 
diluted into 100µl of Hank’s Balanced Salt Solution (HBSS) which had been treated 
(with either HCl or NaOH) to have a pH of 6.0, 6.5, 7.0, 7.5 or 8.0 and incubated at room 
temperature for 30 minutes. Treated vector was then added to duplicate wells of cells and 
the procedure continued as with tissue culture cell lines.  
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Cell counting by flow cytometry 
 After allowing GFP expression to progress for 72 hrs, cells were detached with 
0.25% trypsin, collected and duplicate wells pooled together. Cells were centrifuged at 
500xg for 5 min and resuspended in 200 µl phosphate buffered saline (PBS). Collected 
cells were brought to the flow cytometry facility and assayed for GFP expression. The 
acquisition and analysis of flow cytometry data was performed on a FACSCalibur flow 
cytometer (BD Biosciences; San Jose, CA). Untransduced cells of each type were used to 
set a forward scatter (FSC) threshold, which was used to eliminate much of the 
subcellular debris. GFP fluorescence was observed and the samples gated electronically 
to eliminate debris.  In determining the transduction efficiency of each vector preparation 
in each cell line, a minimum of 2x104 events were analyzed per sample. A Z-test for two 
proportions was used to determine significance between vector preparations; p<0.05 was 
considered significant.  
 
In vivo transduction 
 Sprague-Dawley rats (Harlan Labratories Inc; Indianapolis, IN) weighing between 
200-250 grams (approximately 3 months of age) were used. Each rat was deeply 
anaesthetized with a ketamine/xylazine solution (67 mg/kg ketamine and 6.7 mg/kg 
xylazine) and placed in a sterotaxic frame. The cranium was exposed via a midline 
sagittal incision and a burr hole drilled at -0.3 mm Bregma, 3.5 mm lateral and a glass 
needle inserted 1.5mm deep into the cortex. A micropump was used to inject 5 µl of the 
viral solution at a rate of 200 nl/min. Virus was previously diluted so that all vectors 
preparations contained a total of 2.5 x 106 TU’s. The needle was left in place for an 
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additional 5 minutes after the injection of viral solution was completed before being 
withdrawn gradually over a period of 2 minutes. The scalp was then sutured and the 
animal allowed to recover.  
 
Immunostaining and cell counting 
 One week following viral injection, animals were anaesthetized with 
ketamine/xylazine and perfused transcardially with 4% paraformaldehyde and the brains 
harvested. Brains were post-fixed overnight in 4% paraformaldehyde and then cryo-
protected in 30% sucrose. In order to assess the tropism of each vector, the brains were 
cut into 30 µM coronal sections using a cryostat and divided into six serial sets. Sections 
were immunostained with either mouse anti-NeuN (1:250; Millipore) or rabbit anti-
GFAP (1:1000; Abcam; Cambridge, MA) overnight at room temperature, followed by 
incubation with appropriate secondary antibody for 2 hrs (goat anti-mouse IgG at 1:250 
or goat anti-rabbit IgG at 1:250; Jackson ImmunoResearch) at room temperature. All 
GFP positive cells were counted from at least five fields around the injection site, and the 
percentage of co-labeled GFAP (Fig. 2-7) or NeuN (Fig. 2-8) positive cells was 
determined. GFP positive cells which stained for neither GFAP nor NeuN were 
considered “unidentified.”  
For each cell line and harvest length, the transduction from three separate animals 
was recorded and an average of these numbers reported along with SEM. Significant 
difference between vectors, as a result of harvest length and/or producer cell line was 
determined via two-way ANOVA; p<0.05 was considered significant. 
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Results 
 
pH of viral harvest media  
To determine the pH of the lentiviral vector harvest media produced in the 
different cell lines and at different harvest lengths, vector containing supernatants were 
collected at the various appropriate time points. The 293FT cells had yet to completely 
reach confluency by the 40 hr harvest, and the media was still red in color. However, in 
dishes reserved for the 64 hr harvest the media had progressed to an orange-yellow color 
and cells were beginning to detach. Despite being considered slower growing, 293T cells 
had a similar appearance at the same time points. Supernatants from 293FT cells had an 
average pH of 7.17 +/- 0.02 after 40 hrs, while an additional 24 hrs in culture had 
significantly lowered the pH to 6.72 +/- 0.03. The vector containing supernatants from 
293T host cells followed a similar, albeit lower, pattern with a pH of 6.98 +/- 0.03 after 
40 hrs and 6.55 +/- 0.02 after 64 hrs (Fig. 2-1b). The pH changes between cell lines 
(293T vs. 293FT) and harvest length (40hr vs. 64hr), were significant at a p<0.001.  
 
Transduction efficacy in tissue culture cell lines 
 To determine if pH can directly alter the infectivity, aliquots of lentiviral vector 
from a single batch were incubated at different pH’s before testing their ability to 
transduce 293FT cells in culture. When vector was incubated in HBSS treated to pH 7.5 
(which is close in pH to the solution used to resuspend the vector) it transduced 90.0% of 
cells (Fig. 2-2). When the pH of the HBSS was reduced to 7.0, the percentage increased 
to 94.6%. Decreasing the pH to 6.5 increased the transduction further (96.6%), though a 
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decrease to 6.0 did not result in an additional increase in infectivity. An increase in pH, to 
8.0, resulted in a significant decrease in infectivity (to 71.0%). 
In order to establish if the harvest media pH difference’s resulted in a change in 
the functionality of the vectors, several different common tissue culture cell lines (293FT, 
U373, PC12 and SH SY5Y) were transduced at constant MOI of 100. After allowing the 
GFP reporter gene to express for 72 hrs, the cells were harvested, pooled and taken for 
analysis by flow cytometry. In all four cell lines tested, the 40 hr harvest produced in 
293T cells had the highest efficacy (Table 2-1 and Fig. 2-3) and when comparing within 
producer cells the 40 hr harvest had a higher transduction efficiency than its 
corresponding 64 hr harvest. The 40 hr harvest produced in 293T cells resulted in a 
transduction efficiency of over 99%, while its corresponding 64 hr harvest had a 
transduction efficiency of 88.3% (one of the two times the 293T 64 hr harvest performed 
better then the 293FT 40 hr harvest). The vector produced in 293FT displayed a similar 
pattern when used to transduce 293FT cells (Fig. 2-3a), though at lower levels, with 
76.5% and 47.9% (40 hr and 64 hr) respectively. U373 astrocytoma cells (Fig. 2-3b) 
could be transduced at similarly high levels with vector produced in 293T cells, which 
transduced 99.8% and 92.4% of cells (40 & 64hr respectively). Vector produced in 
293FT cells transduced 87.9% and 61.2% of the cells. SH SY5Y (Fig. 2-3c) 
neuroblastoma cells were transduced at 73.6, 41.6, 62.0 and 30.3% (293T 40hr, 64hr and 
293FT 40 and 64hr, respectively). PC12 cells (Fig. 2-3d) had the poorest transduction 
efficiency with the 293T 40hr harvest time resulting in just over 50% transduction and in 
the remaining harvests fewer than 35% were transduced.  
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Transduction efficacy in rat primary astrocytes 
 As with the tissue culture cell lines, when rat primary astrocytes (MOI = 100) 
were transduced with vectors produced via the different harvest lengths and producer cell 
lines, the 293T 40hr harvest had the highest transduction efficacy (Fig. 2-4). The other 
vectors had significantly lower efficacies, with both the 293FT 40 hr and 293T 64 hr in 
the 50% range and the 293FT 64hr harvest at 34%. 
 
Neuronal transduction efficacy in rat dorsal root ganglion cultures 
 To determine if there was a tropism difference, as opposed to a decreased efficacy 
of vectors produced at longer harvest times, rat dorsal root ganglion cultures were 
transduced at a MOI of 100. After allowing the GFP reporter to express for 72 hrs, the 
cells were fixed and immunostained for NeuN (Fig. 2-5 and 2-6). In a pattern opposite to 
that seen with the primary astrocytes and tissue culture cell lines, the 64hr harvests 
transduced with a higher efficacy then their 40 hr counterparts. When comparing vectors 
produced in 293FT cells to vector produced in 293T cells, there was a 15% increase in 
neuronal transduction (Fig. 2-5), while when using vectors produced in 293T cells there 
was no real difference between harvest lengths (though both vectors had a significantly 
higher efficacy then those produced in 293FT cells). For DRG neurons the producer cell 
line had a significant overall impact on transduction efficiency, with lentivirus produced 
in 293T cells outperforming the vector produced in 293FT cells regardless of harvest 
length.  
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Tropism in vivo in motor cortex 
 Rats were injected with equal titers (based on p24 estimation) of lentiviral vectors 
carrying the GFP gene into motor cortex. One week later, animals were euthanized and 
brain tissue was treated as indicated in the methods. 
 All of the GFP positive cells from a single set of serial sections were counted and 
the subset of these cells that were also positive for immunofluorescence (either GFAP or 
NeuN) were counted. Results are expressed as a percentage of transduced cells (GFP 
positive), which are astrocytes or neurons. Of the GFP positive cells, astrocytes make up 
60-80% for all four vectors tested (Fig. 2-7, Fig. 2-9a). Similar to what was seen in vitro 
with DRG neurons, the producer cell line had a significant effect on the transduction 
efficiency with lentivirus produced in 293FT cells performing the best (p<0.05). Neurons 
make up a much smaller percentage, with the highest transduction coming from the 
293FT 64hr harvest at 10% (Fig. 2-8, Fig. 2-9b). The other vector preparations resulted in 
transduced neurons composing 4-7% of the total transduced cells.  
 If the ratio of transduced glia to neurons is assessed (Fig. 2-9c), then the 293FT 
40hr vector appears as the most preferential for astrocytes and the 293FT 64hr 
preparation the most preferential for neurons. While still biased towards transducing glia 
over neurons, the 293FT 64hr vector’s ratio was over 3 fold lower than the 293FT 40hr 
vector (7:1 glia to neuron compared to 20:1).  
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Discussion 
These studies show that producing and harvesting VSVG pseudotyped lentiviral 
vectors under different conditions can alter their ability to transduce cells both in vitro 
and in vivo. It has been suggested that harvest media pH and the lot of serum used in 
production of the virus lead to a change in efficacy and tropism [120]. The cells used to 
produce virus were all cultured in the same lot of serum, eliminating that variable from 
consideration in determining our vectors efficacy.  
The vesicular stomatitis virus and its surface envelope protein have long been 
studied as a model system for viral membrane fusion [148-150]. As a result, much is 
known about VSVG’s response to different pH’s. Pretreatment at lower pH’s can 
increase vector infectivity [144] and pre-incubation of vector at different pH’s does have 
a direct impact on the vector’s ability to transduce cells in culture, with lower pH’s 
increasing infectivity. If pH is not the direct cause for the changes in tropism and 
infectivity, the remaining differences in the vectors would include some intrinsic 
difference between the producer cells and changes in those cells as the harvest incubation 
time progresses 
These studies show the use of 293T cells in place of 293FT as the producer cell 
line improved the resulting vectors efficacy on cells in culture. Similarly the shorter 
harvest length (40 hrs) performed better then the corresponding 64 hr harvest length in 
vitro. However, in vivo, that pattern was somewhat different. The best performing vector 
in the cortex for transducing neurons was produced in 293FT cells and harvested after 64 
hrs. If pH were the sole determinant of vector efficacy then it would be expected that 
vectors would align: 293T 64hr, 293FT 64hr, 293T 40hr then 293FT 40hr in terms of 
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their transduction efficiency. While pH changes are the most obvious differences between 
all the culture conditions, it is unclear if this is the main underlying cause in the changes 
in tropism, as the changes in transduction do not strictly follow any related changes in 
pH.  
Studies have shown many different circumstances that can influence vector 
infectivity: Higher cholesterol content in the producer cell membranes can increase 
infectivity of vectors pseudotyped with VSVG [151, 152]. Chondroitin sulfate 
proteoglycans (CSPGs) in the viral supernatant can alter infectivity as well [153]. It has 
been shown previously that cellular components and serum [154] can be present in 
lentiviral vector preparations and lead to an immune response and poorer transduction 
efficiency in transduced animals. Moreover, highly purified lentiviral vector preparations, 
or vector produced in the absence of serum do appear to have a higher effective titer 
[155]. As the longer harvest times had lower transduction efficiencies in vitro, it is 
possible that as the cells stay in culture longer during the production cycle, some factor 
with a negative impact on viral efficacy builds up resulting in reduced lentiviral vector 
quality. In fact, this has been shown in the production of adenoviral vectors where 
increased cell densities (as would be seen at longer lentiviral harvest time-points due to 
continued division of the producer cells) actually result in lower viral efficacy [156]. 
The potential for altered harvest conditions resulting in an altered tropism/efficacy 
provides an attractive and simple tool to more selectively target specific subpopulations 
of cells. In addition, this indicates that production conditions should be carefully 
monitored in order improve the overall quality and consistency of the vector preparation. 
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Chapter Three 
 
Introduction 
Current gene therapy strategies employed for the treatment of chronic pain have 
had some modest successes [157-159], including a progression to clinical trials. The 
therapeutic interventions utilized are successful in bringing about a benefit but still suffer 
from lack of specificity, showing transduction of other sensory neurons can lead to 
unwanted side effects and continued impairment. These studies attempt to produce a 
chimeric pseudotype to target lentiviral vectors specifically to nociceptive sensory 
neurons in dorsal root ganglia.  
 
Chronic Pain 
 Chronic pain is a broad category of conditions characterized by inappropriate and 
long-lasting pain. There are a wide variety of causes for this persistent pain, from diabetic 
associated neuropathies and cancer associated pain to actual direct injury of the nerves. 
Pain conditions of this type are often severely debilitating and have significant impacts 
on quality of life. Various medications, such as antidepressants and opiods and 
analgesics, have been used to treat pain [160]. Treatments of this sort have often suffered 
from addiction potential and decreased efficacy over time as well as unwanted side 
effects in other systems.  
 Gene therapy has been successfully employed to treat chronic pain in animal 
systems through the delivery of genes such as proenkephalins, glutamic acid 
decarboxylase (GAD), BDNF, siRNA’s for Nav1.3 and 1.8 sodium channels [157-159, 
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161] to name a few. Herpes Simplex and adeno-associated vectors have been utilized 
[162, 163] to deliver these genes to sensory neurons but both suffer from a lack of 
specificity for nociceptive sensory neurons. This can lead to unwanted side effects 
through modulation of other sensory neurons functionality.  
 
Neurotrophin Signaling and Receptor Localization 
  Neurotrophins are a family of neuronal growth factors that signal for survival, 
differentiation, neurite growth and guidance [164].  Members of the family include brain-
derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5) 
[165, 166], neurotrophin-6 (NT-6) [167] and the best-characterized member of the 
family, nerve growth factor (NGF) (Fig. 3-1).  All of the neurotrophin family members 
are highly homologous proteins that can form hetero- and homodimers.  Neurotrophin 
signaling is mediated through both the p75NTR, a member of the tumor necrosis factor 
receptor family, and the Trk receptors (TrkA-C), which are receptor tyrosine kinases 
[168, 169].  The p75NTR is fairly universal in its low affinity binding of all the members 
of the neurotrophin family [170], while the Trk receptors specifically bind their ligands 
with high affinity. TrkA is the receptor for NGF [168, 169] and the specificity of this 
interaction is determined by loops 2 and 4 of NGF [169] shown in Figure 3-1.  These 
loops have been used as targets for the production of therapeutic peptide mimics for 
treating different diseases through activation of the neurotrophin receptors [171, 172].  
Mimetics of β-turns like those in loop 2 of NGF have been shown to be sufficient for 
binding and activation of the TrkA receptor [173, 174] without the formation of an NGF 
dimer. 
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   TrkA receptor expression is constrained to specific regions of the brain and 
spinal cord, primarily localizing to the superficial laminae of the spinal cord [175], the 
sensory dorsal roots [176] and in the hippocampus and cerebellum of the brain [177].  
TrkA expression is up-regulated in chronic pain conditions such as arthritis, and this 
increase in NGF responsiveness is thought to be associated with long-term changes such 
as higher sensitivity and increased activity of pain fibers [178-180].  TrkA expression 
patterns also change after injury [181], and the sprouting of NGF-responsive sensory 
neurons is one of the factors that can lead to autonomic dysreflexia after spinal cord 
injury [182].  
 Since all Trk-A expressing sensory neurons are nociceptive [183, 184] and to 
alleviate this problem of improper targeting, these studies intend to generate the novel 
NGF-VSVG pseudotypes for lentiviral vectors. This would allow for the specific delivery 
of pain modulatory genes to the nociceptive sensory neurons.  
 
Chimeric Pseudotyping 
 In addition to using the native tropism of viral glycoproteins, some glycoproteins 
can be engineered to gain specificity for novel cellular targets.  This can be achieved 
through the insertion of antibody [185] or biotin [186, 187] binding regions into the 
glycoprotein.  Alternatively, direct incorporation of antibodies [185, 188] or other 
polypeptides [189] has been used to create new targeting profiles.  Similar strategies have 
been employed in non-enveloped vectors such as adenovirus and adeno-associated virus 
[190-192]. Studies for engineering novel targeting profiles have been mostly attempted 
using the Sindbis virus or murine leukemia virus glycoproteins as a base.  
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 Utilizing VSVG as a foundation to create a chimeric pseudotype for lentivectors 
will allow targeting of therapeutic genes to a subset of neurons. The novel targeting will 
be achieved by the replacement of the extracellular domain of VSVG with mature NGF, 
which will target the vector to TrkA-expressing nociceptive neurons. . To this point in 
time, three different successful schemes for utilizing VSVG to create targeting chimeras 
have been published (Fig. 4-2): 1). Replacement of the ectodomain with avidin or 
streptavidin [193, 194], 2). Insertion of a large targeting molecule at the n-terminus [195] 
and 3). Insertion of short targeting sequences at the n-terminus [196, 197].  
 When major modifications to the extracellular domain of a viral glycoprotein are 
made in an effort to alter its tropism, an additional “fusogenic” glycoprotein will need to 
be expressed as part of the lentivirus vector. These fusogenic molecules are other viral 
glycoproteins that have been mutated such that their receptor binding abilities have been 
abolished (or greatly reduced) [198, 199]. In the constructs utilized in this dissertation, 
NGF replaces the domains containing the portion of VSVG required for membrane 
fusion, therefore HAtmt (or a similar molecule) would need to be incorporated into any 
vectors.  
 
Viral Glycoprotein Folding and Trafficking 
Conceptually, inserting novel binding regions is a very simple strategy, but there 
are many complications that come with disrupting the complex machinery of a viral 
envelope glycoprotein not limited to effecting their ability to induce membrane fusion 
[200]. Guibinga et al [196] show that an insertion of a short (10 amino acid) peptide near 
the n-terminal end of VSVG results in the protein being misfolded and sequestered at 
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normal cell culture temperatures, though surface expression could be rescued by culturing 
at 30°C.  
Viral glycoproteins are synthesized by the ribosomes of the rough endoplasmic 
reticulum such that the extracellular domain(s) of the glycoprotein reside within the ER 
and undergo folding there. Folding occurs concomitantly with synthesis, and for VSVG, 
is largely completed very quickly (<5min) [201]. In order for VSVG to be transported 
from the ER to the golgi and then the cell surface, a sequence of events must take place: 
initially protein is synthesized into the ER lumen, then n-linked glycosylation occurs and 
proteins are shuttled through a cycle of cleaving and adding glucose molecules while 
bound to chaperones, all the while undergoing a continuous cycle of folding. Properly 
folded proteins are released from the chaperone molecules and the final glucose (along 
with a mannose) removed, signaling the protein is free to be trafficked to the golgi 
(reviewed in [202-204]). The signal to escape the folding cycle is thought to not just be 
limited to proper tertiary structure, but protein oligomerization [205] as well. Misfolded 
proteins are recognized (through exposure of hydrophobic domains or other means) and 
fed into the Endoplasmic Reticulum-Associated Degradation pathway (ERAD). The 
ERAD pathway requires the binding of select chaperones such as BIP [206] and PDIs, 
which then forms the complex required for ERAD. The misfolded glycoprotein is then 
retro-translocated into the cytosol through the sec61 translocon [207] where it is degraded 
by the 26s proteosome concomitantly with its translocation [208, 209]. 
These studies will determine the feasibility of targeting lentiviral vectors to 
nociceptive sensory neurons using novel chimeras of NGF and VSVG. 
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Materials and Methods  
 
Construction of NGF-VSVG chimera 
 The initial NGF to VSVG fusion construct was designed to utilize the 
transmembrane and cytoplasmic domains of VSVG protein (amino acids 446-495), with a 
flag tag acting as a linker to the mature form of NGF (Fig. 3-2a). This construct was then 
synthesized by Integrated DNA Technologies (IDT; Caralville, IA) and delivered as the 
kanamycin and ampicillin resistant pGOv4-NV shuttle vector. The NV gene was then 
transferred into an expression vector compatible with 3rd generation lentiviral vectors 
using EcoRI sites, creating pLp-NV.  
 The second generation NGF-VSVG (NV v.2) (Fig. 3-2b) chimera was designed in 
the same manner as the previous vector, but includes an additional 21 amino acids of 
VSVG’s extracellular domain as well as its 15 amino acid n-terminal signal sequence. 
This construct was also synthesized by IDT and delivered as the pUC-NV v.2 shuttle 
vector. The NV gene was then transferred into an expression vector compatible with 3rd 
generation lentiviral vectors using EcoRI sites, creating pLp-NV v2.  
 A construct (pCMV-VSVGED) consisting of the baculovirus gp64 n-terminal 
signal sequence followed by a multiple cloning site and then 21 amino acids of VSVG’s 
extracellular domain along with the it’s transmembrane and cytoplasmic domains (Fig. 3-
2c), was obtained from the Yla-Herttuala lab (University of Kuopio, Finland) [193, 210]. 
The mature form of NGF was amplified out of the pXCRSV-NGF to add the proper 
restriction sites (5’ PstI, 3’ SmaI) and then cloned into the pCMV-VSVGED vector. This 
creates the pCMV-VSVGED/NGF vector.  
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Construction of VSVG-GDNF chimera 
 Glial-derived neurotrophic factor (GDNF) was amplified out of the pBOB-GDNF 
vector to add the proper restriction sites (5’ PstI, 3’ SmaI) and then cloned into the 
pCMV-VSVGED vector, creating pCMV-VSVGED/GDNF (Fig 3-2d).  
 
Chimeric glycoprotein RNA production 
 HEK 293FT cells were transiently transfected with plasmids encoding the chimeric 
glycoproteins using Lipofectamine. Protein was allowed to express for 48 hrs before 
determination of RNA expression was made.  
 Messenger RNA was harvested using the Qiagen RNeasy Protect kit, according to 
its protocol. The resulting purified RNA was then reverse transcribed using the 
Accuscript cDNA synthesis kit (Agilent; 200820), and the target sequence amplified 
according to the manufacturer’s protocol and NGF specific primers. The RT-PCR 
product was then run on a 1% gel agarose gel and the results documented. 
 
Western Blots of chimeric glycoprotein expression 
 HEK 293FT cells were transiently transfected with plasmids encoding the chimeric 
glycoproteins using Lipofectamine. Protein was allowed to express for 48 hrs before 
determination of protein expression was made. 
 To harvest cell lysates, transfected cells in 6-well plates were washed with HBSS 
and then Laemli’s buffer added to each well. Cells were then dislodged using a cell 
scraper and the resulting lysates transferred to an eppendorf tube. Lysates were sonicated 
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for 15 seconds and then boiled for 10 minutes. Equal volumes of the cell lysates were 
then loaded into a 4-20% gradient gel (Bio-Rad,) and run at 100 V. Proteins were 
transferred from the gel to a nitrocellulose membrane, which was blocked for 2 hrs in 5% 
milk in TBS. The membrane was then immunostained overnight with the appropriate 
antibody (1:1000 dilution of rabbit α-VSVG tag (Abcam; ab1874) or 1:1000 dilution of 
mouse α-FlagM2 (Stratagene; 200472-21)), and then the coordinate secondary (goat α-
mouse AlexaFluor 680 (Molecular Probes; A21048) or goat α-rabbit AlexFluor 680 
(Molecular Probes; A-21076)) at a dilution of 1:30000. Finished, stained blots were 
imaged on a LiCOR Odyssey machine. 
 To determine if the chimeric proteins were successfully being trafficked to the cell 
surface, the surface component of cells were biotinylated and then those proteins 
harvested using the Cell Surface Protein Isolation Kit (Pierce; 89881) following the 
manufacturer’s protocol. 10-cm dishes of HEK 293FT cells were transfected with 
plasmids encoding the chimeric glycoproteins and allowed to express protein for 48hrs. 
Cells were then washed twice with cold PBS, the Sulfo-NHS-SS-Biotin solution added 
and the dishes allowed to rock gently for 30 minutes at 4°C. The labeled cells were 
quenched, harvested and lysed. The resulting lysate was run through an avidin-agarose 
column to bind biotinylated proteins. Equal volumes of the biotinylated protein were then 
loaded into a 4-20% gradient gel (Bio-Rad,) and the western blot procedure continued as 
with cell lysates. 
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Immunocytochemistry of chimeric glycoprotein expression 
 HEK 293FT cells were transiently transfected with plasmids encoding the chimeric 
glycoproteins using Lipofectamine. Protein was allowed to express for 48 hrs (either at 
37°C or 32°C as indicated) before cells were fixed with 4% paraformaldehyde. Cells 
were then blocked with 5% Normal Goat Serum (NGS) in dilution buffer (25mM Tris-
HCL, 300mM NaCl, 0.4% Triton X-100, 0.2% BSA and 0.1mM Thimerosol) at room 
temperature for 1hr. Immunostaining was performed for 3 hrs using rabbit α-NGF 
(Abcam; Ab6199) (1:200), rabbit α-VSVG tag (1:100) or mouse α-FlagM2 (1:100) 
followed by either goat α-mouse Texas Red (Jackson Immuno; 115-095-166) or goat α-
rabbit Texas Red (Jackson Immuno; 115-075-045) (both at 1:250) for 1 hr.  
 
Colocalization 
 In order to determine colocalization of the various chimeras, 293FT cells plated on 
0.1% Poly-l Lysine coated chamber slides (Nalg Nunc; 154917) were transiently 
transfected as before and allowed to express the transgenes for 24 hrs. Cells were fixed 
with 4% PFA for five minutes at 37°C, then washed in 0.1M PBS and blocked for 1hr in 
5% NGS in dilution buffer at room temperature. Immunostaining was performed using 
rabbit α-VSVG tag (1:100) and mouse α-calnexin (Abcam; Ab31290) (1:250) for one 
hour at room temperature followed by goat α-mouse Texas Red and goat α-rabbit FITC 
(both at 1:250) for one hour at room temperature. Hoechst dye was diluted to 5µg/ml in 
water and added to cells for 10 minutes at the conclusion of the immunostaining. Cells 
were then washed twice in 0.1M PBS and the slides dried before the addition of 
Fluoromount-G (Southern Biotech) and coverslipping.  
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 Slides were imaged on an Olympus IX81 DSU microscope, and z-stacks captured 
at 60x of multiple representative fields using the Slidebook imaging program (Intelligent 
Imaging Innovations; Denver, CO). The z-stacks were separated into individual planes 
and saved, with each channel represented as an individual 16-bit tiff file. In order to 
quantify the degree of colocalization, the image outputs were transferred to the Image Pro 
Plus software (MediaCybernetics; Bethesda, Md). Areas of interest (AOI’s) were drawn 
around cells expressing the chimeras (or control proteins) and the colocalization 
calculated. The main value provided to quantify colocalization is the Pearson’s 
Correlation Coefficient (Pearson’s Rr), which falls on a scale of -1 to +1. When analyzing 
Pearson’s Correlation Coefficients a value of zero indicates that there is no significant 
correlation between the two variables and any colocalization seen is purely random. As 
values approach +1 it indicates an increasingly strong correlation, with a value of +1 
meaning that where there is variable “X” there is also variable “Y”. The Pearson’s 
Correlation Coefficient is bidirectional, such that a value indicates the correlation 
coefficient of “where there is X there is Y” and “where there is Y there is X”. A Person’s 
Rr of -1 indicates that where there is variable “X” there is not “Y”. 
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Results 
 
Expression of NGF-VSVG Chimeras 
 After transiently transfecting the pLp-NV construct into HEK 293FT cells, 
immunocytochemistry was performed to assay expression using a polyclonal antibody to 
NGF. No staining was observed (not shown) using this antibody.  
 The second generation of NGF-VSVG (NV v.2 and VSVGED/NGF) chimeras were 
transiently transfected into HEK 293FT cells and cells lysates run on 4-20% 
polyacrylamide gel and transferred to a nitrocellulose membrane. Membranes were 
immunostained with the rabbit α-NGF antibody, and as with the original constructs no 
bands were seen (Fig. 3-3a).  
 To ensure that messenger RNA was actively being produced, RNA was harvested 
from transfected cells, and used as a template to perform reverse-transcription PCR. 
Three clones of each chimera were tested (Fig. 3-3b) and messenger RNA was in fact 
successfully being produced in transfected cells as indicated by a band of approximately 
380 bp, the same as seen in control reactions.  
 The second version of NGF-VSVG (NV v.2) constructs included a flag-tag, 
providing an additional means of detection. Cell lysates were run on a polyacrylamide gel 
as before, and the membranes immunostained with the α-flagM2 antibody. All three NV 
v.2 clones gave a band of approximately 24 kDa (Fig. 3-4a), which was close to the 
predicted size of 22 kDa based on the amino acid sequence.  
 To determine if the VSVGED/NGF chimera was also being expressed, western 
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blots were again performed and immunostained with the α-VSVG tag antibody.  All three 
clones showed a band of approximately 24 kDa, as did the NV v.2 clone run along with 
them (Fig 3-4b).  
 
Localization of Chimera Expression 
 To ascertain if the chimeric glycoproteins were being trafficked to the cell surface, 
transfected cells had their extracellular proteins biotinylated and collected. Western blots 
of the surface proteins were then stained for the VSVG tag (Fig. 3-5a) or flag tag (Fig. 3-
5b) immunoreactivity. Neither western blot showed any bands, indicating a lack of any 
significant surface expression, except for controls.  Both the VSVG (Fig. 3-5a) and 
NCAM-flag (Fig. 3-5b) controls showed appropriate surface expression.   
 In order to determine if the chimeric proteins were being sequestered in the 
endoplasmic reticulum, immunocytochemistry was performed on transiently transfected 
cells using an antibody to the VSVG tag along with an antibody to the ER marker 
calnexin. Pearson’s Correlation Coefficients were determined using Image Pro Plus 
software to analyze 60x images and the averages reported here (Fig. 3-6). As a control, 
cells were transfected with a plasmid to GFP and the colocalization of GFP with calnexin 
staining was determined, giving a Pearson’s Rr of -0.13+/-0.23. This indicates that very 
little GFP co-localized to the ER where calnexin is localized.  An additional negative 
control was determining the colocalization between Hoechst (a DNA dye) and calnexin 
staining, which gave a Pearson’s Rr of -0.35+/-0.25. Colocalization of over-expressed 
wild-type VSVG with calnexin showed a Pearson’s Rr of 0.39+/-0.18, and when VSVG 
was compared to NCAM-flag over-expression the Pearson’s Rr was 0.69+/-0.14.  Both of 
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these indicate a positive correlation where VSVG co-localized more strongly with 
NCAM than calnexin. The colocalizations of the VSVGED/NGF and NV v.2 chimeras 
with calnexin were 0.856+/-0.08 and 0.87+/-0.05 respectively. VSVGED/GDNF’s 
colocalization with calnexin was also determined, resulting in a Pearson’s Rr of 0.61+/-
0.19.  These data indicate a strong co-localization of VSVED/NGF and NV v.2 to the ER.  
 Additional cells were transfected to allow protein expression under lower 
temperatures (32°C as opposed to 37°C) as this has been shown to improve folding of 
some recombinant proteins. When immunostained with an antibody to VSVtag all of the 
chimeric clones showed expression (VSVGED/NGF, NV v2 and VSVGED/GDNF) as 
shown in Figure 3-7 b-d, however staining patterns appear very similar to those seen 
when cells were incubated at 37°C. 
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Discussion  
The strategies proposed in these studies, however promising, did not successfully 
result in functional chimeric targeting proteins. Despite their failure to create a novel 
targeting pseudotype, these studies do provide interesting information on what 
combinations of targeting molecules (NGF/GDNF) and base molecules (VSVG) can be 
compatible. They also retain the potential to be successful in other combinations in the 
future. 
The initial strategy for creating a chimeric viral glycoprotein to target lentiviral 
vectors to a specific subpopulation of neurons involved the fusing of full-length mature 
NGF to the transmembrane and cytoplasmic domains of VSVG (NGF-VSVG) (Fig. 3-
1a). In this construct, a flag-tag was utilized as a spacer to position the NGF farther from 
the plasma membrane and aid in the resulting chimera’s ability to fold properly. Upon 
expressing this chimera in cells, no expression was seen when using an antibody to NGF. 
Previous studies by Guan et al. [211] indicated that the direct coupling of a secreted 
protein to the transmembrane domain of VSVG did not lead to the expected cell surface 
expression, instead protein was sequestered in the endoplasmic reticulum and golgi.  
Given that in this construct, NGF would be located in close proximity to the cell 
membrane and the lack of signal sequence associated with transmembrane proteins this is 
not an unexpected outcome.  
 In order to address these probable impediments to functional expression, a new 
construct was created which included 21 additional extracellular amino acids from VSVG 
as well as the glycoprotein’s leader/signal sequence (Fig. 3-1b). Additionally, a similar 
construct was obtained from the Yla-Herttuala lab (University of Kuopio, Finland) that 
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had previously been shown to be an effective retargeting platform [193, 210] using 
different targeting molecules. The main differences in this vector (pCMV-VSVGED) as 
compared to the NV v.2 vector are the utilization of the signal sequence from baculovirus 
gp64 in place of VSVG’s signal sequence and the deletion of the flag-tag. Western blots 
on these cell lysates were immunostained with an antibody to NGF, and none of the 
clones tested showed expression. Due to this lack of expression, cellular transfections 
were repeated and RNA harvested so that it could be determined if mRNA was 
effectively being produced. As shown in Figure 3-3b, after RT-PCR all six clones gave a 
band of the appropriate size.  This indicates that while cells are producing mRNA 
encoding the chimeras, there is a problem with protein expression. To determine whether 
this was due to a complete lack of protein production, or some difficulty associated with 
NGF antibody staining, additional western blots were performed on the cell lysates and 
probed with antibodies to either the flag-tag included in the NV v.2 chimera’s or to the 
cytoplasmic domain of VSVG which would allow the detection of all of the chimera’s. 
Appropriate bands were seen for all of the chimeras tested.  
 While western blots on cell lysates will show if any protein is being produced, it 
does not indicate whether or not that expression is at the cellular surface (where it needs 
to be in order to functionally be incorporated into lentivirus) or if it is trapped 
intracellularly. To begin to ascertain the localization of expression, the cell surface 
proteins were biotinylated and selectively harvested in order to determine if any of the 
chimeras were successfully trafficked to cell membrane. Western blots of the biotinylated 
proteins, showed no bands from any of the clones tested whether they were stained for 
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the VSVG tag (VSVGED/NGF and NV v.2) or for the flag tag (NV v.2). This shows that 
the protein is in fact being sequestered somewhere intracellularly. 
 In order to determine the location of the chimeras within the cell, colocalization of 
chimera expression with a marker of the ER was determined. The NGF containing 
chimeras showed a very strong correlation with ER, both having Pearson’s Rr’s over 0.8. 
Comparing this to the Rr determined for wt VSVG (0.39+/-.18) a considerable difference 
can be seen. As this colocalization is determined via single instance in time, it is not 
surprising to find some portion of VSVG in the ER before it is trafficked to the golgi and 
then the cell surface (especially in situations of over-expression). And due to the fact that 
some VSVG is supposed to be in the ER at any given time and calnexin is known folding 
chaperone of glycoproteins, a value too close to zero (random colocalization) would be 
inappropriate. VSVG and NCAM-flag had an Rr of 0.69+/-0.13, a strong correlation. This 
value could be expected to be higher, as both reside in the cell membrane. However, 
different subsections of the cellular membrane may be enriched for one of the proteins 
over the other. 
 Misfolded wild-type VSVG has been shown to be largely retained in the 
endoplasmic reticulum or golgi [211], and often when chimeric proteins are formed their 
native stability is compromised and culturing at a lower temperature can help to increase 
chimeric protein expression [196]. When several VSVGED/NGF and NV v.2 clones were 
expressed at 32°C, each of them expressed and showed a similar pattern to when the 
chimeras were expressed at 37°C. This would seem to indicate that the lowered 
temperature did not significantly improve the expression pattern of the chimeras and that 
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if the lack of cell surface expression is in fact due to misfolding (as is likely), this 
misfolding cannot be resolved by lowering the culture temperature.  
 Signal sequences on proteins are important for ensuring their proper expression, 
trafficking, and localization. Thus, inappropriate signal/leader sequence could lead to the 
difficulties seen in these studies. The two different base constructs used in these studies 
were chosen such that this would not be a contributing factor. As discussed previously, 
the main difference between VSVGED/NGF and NV v.2 is the signal/leader sequence at 
the amino-terminus of the protein. The VSVGED/NGF construct utilizes the SS/L from 
the baculovirus GP64 glycoprotein, while NV v.2 uses VSVG’s SS/L. Given that 
expression patterns and colocalization values for each construct were virtually identical, 
it would seem unlikely that this is the cause for the lack of cell surface expression. 
There is potential that the lack of cell surface expression could also be due to the 
fact that some intrinsic quality of NGF was incompatible with anchoring it to the cell 
membrane as part of a chimeric protein with VSVG. To control for this possibility, the 
mature form of glial-derived neurotrophic factor (GDNF) was cloned into the VSVGED 
vector in the same manner as with the VSVGED/NGF vector (Fig. 3-1d). GDNF is 
similar in size and is a secreted protein similar in nature to NGF providing an appropriate 
control that if trafficked to the cell surface would also be relevant for targeting lentiviral 
vectors. VSVGED/GDNF also strongly colocalized with the ER, and expressing the 
protein at lower temperatures did not alter the expression pattern (Fig. 3-7), as seen with 
the NGF chimeras.  
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 Expression of chimeric glycoproteins did result in detectable protein production 
as shown via immunocytochemistry and western blot, but not in an apparently functional 
form as shown by a lack of cell surface expression and vector infectivity. The results 
presented here suggest that utilizing full-length growth factors (either nerve growth factor 
or glial-cell derived neurotrophic factor) may not be suitable for the directed targeting of 
subpopulations of neurons when fused with VSVG.
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Chapter Four 
Discussion 
 
 These studies have described two different strategies to alter the tropism of 
lentiviral vectors. The first strategy utilized simple changes in the production protocol, 
while the second created novel chimeras of VSVG. Neither method was entirely 
successful in altering lentiviral tropism, however both provided interesting information 
that may ultimately lead to more successful strategies. Each of these studies will be 
discussed separately in more detail, to lay out potential problems, future directions and 
associated conclusions.  
 
Effects of culture conditions on vector tropism and efficacy 
 Previously, it had been reported that the lowering of the harvest media’s pH seen at 
longer harvest lengths could alter vector transduction preference from neurons to 
astrocytes [120]. The first sets of experiments investigated whether harvest media pH and 
producer cell type affect viral transduction patterns, and if this can be harnessed to tailor 
vector production protocols. In our hands, harvest length and pH does seem to impact 
tropism, but not in the same manner as reported previously. The changes in transduction 
also indicate an overall increase in vector efficacy under some conditions. The studies by 
Hirai et al and those outlined here differ in the pHs seen at the respective harvest lengths. 
Reported values in 293FT cells were 7.2 at 40 hrs and 7.0 at 64 hrs, while our studies 
gave averages of 7.17 and 6.72 respectively. The difference in pH between these two 
studies is negligible at 40 hrs, however by 64 hrs there is a considerable difference. This 
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would seem to indicate a difference in the particular batches of cells used in each study, 
potentially in the metabolic demands of that set of cells.  
If the observed pH’s for virus produced in 293T and 293FT cells are taken 
together, a scale with vector pH’s approximately 0.2 apart is formed. This would allow 
the effects of pH to be determined over a much wider range then previously studied. By 
ignoring harvest cell type and comparing transduction of different pH’s no clear pH 
based preference appears. However, in vivo, a trend towards increased neuronal 
transduction is seen as pH decreases. A pH between 6.72 and 6.55 would appear to be the 
threshold for this effect, as neuronal transduction decreases at the lowest pH tested. It is 
worth noting, that in studies on the effect of pH on wild-type VSV infectivity [144] this is 
the same range where virus began to aggregate at significant levels and this may play a 
role in the difficulty transducing neurons at this pH.  
Even though the two harvest cell types are derived from the same original cell 
line, they do have different growth rates, and therefore likely different characteristics in 
terms of metabolism and waste generation. These possibilities would make it a 
potentially faulty supposition that the transduction efficiencies could be considered on a 
single scale. If the producer cell lines are addressed separately, a pH coordinate change in 
transduction efficiencies can be seen in vitro. Here, virus produced in both 293FT’s and 
293T cells exhibits an increased preference for neurons at lower pH’s along with a 
decreased preference for astrocytes (though with 293T produced virus the difference in 
neuronal transduction is not significant). This pattern is maintained in vivo with virus 
produced by 293FT’s, but not with virus produced by 293T’s. As mentioned previously, 
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this may indicate a threshold where low pH begins to have a detrimental effect on the 
vector.  
During lentiviral production, vector continually buds from the producer cells and 
exists in the supernatant until the desired harvest time when it is collected and the 
purification process begins. The producer cells continue to grow, divide and secrete 
various factors to which the vector is exposed. Of the various changes to the supernatant 
over time, the most readily apparent is the media’s pH, whose decrease can be seen in an 
easily noticeable change in media color. pH is known to affect VSVG, inducing 
conformational changes (reversible), aggregation, protein migration and can even prime 
virus infectivity. These facts and the visible change in harvest media change make 
attributing altered tropism to a change in pH a relatively simple intuitive leap. However, 
is that truly the main culprit here? When virus is produced, it is exposed to media whose 
pH gradually decreases over the length of the harvest. Upon harvesting the virus 
containing supernatants, the virus is spun out of solution and resuspended in media with a 
pH of 7.4 and incubated for six hours before being frozen. Studies on the effect of pH on 
VSVG have shown that changes in activation due to low pH could be reversed by 
resuspension in Tris buffer with a pH of 7.0 in two hours [144]. Coupled with the fact 
that pH induced conformational changes are reversible and that aggregation does not 
begin to reach significant levels until below a pH of 6.8 would seem to make it less likely 
that the lowered pH was having a direct and lasting effect on VSVG. 
The experiments outlined in chapter two describe the transduction characteristics 
of lentiviral vectors, and while it does this in the context of pH and producer cell type, an 
underlying cause for the changes is not determined. In order to understand the dynamics 
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of lentiviral production, it will be important to ascertain the factors that affect tropism 
and efficacy. This will not only increase our knowledge of the system, but if individual 
factors can be isolated it may allow further tailoring of production protocols based upon 
the vectors target. The remainder of this section will describe some potential causes for 
the altered transduction, and outline experimental approaches to assess their relative 
contributions (Fig. 4-1).  
One possible way pH can alter the lentiviral vectors is through aggregation of 
virus in the supernatants. This can be determined visually by electron microscopy on the 
virus containing supernatants. Samples of virus produced under different harvest 
conditions would be clarified, but not concentrated and then treated to undergo electron 
microscopy. Controls of virus produced at a higher pH and then treated with a dilute HCl 
to various pH’s could be used as a basis for comparison. This does not show the amount 
of aggregation seen in purified preparations, and visual determination of aggregation 
would also need to be performed on completely purified samples.  
Another, potentially more quantitative method, is to measure aggregation by 
nanoparticle tracking. Similar to flow cytometry, a laser can be used to measure small 
particles and determine the numbers that fall within certain size ranges. The use of this 
technique has the added benefit of not requiring a labeling step, which eliminates the 
possibility of incomplete sample labeling and detection. The Nanosight machine is 
sensitive enough to detect protein aggregates and molecules down to 30 nm (single 
lentiviral particles should fall in the 80-100 nm range). This technique has not been 
published as having been used to measure virus size or aggregation, but has been used to 
quantify the size and distribution of liposomes (and polystyrene beads) of similar size 
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with a degree of specificity [212]. Though unproven, the application of this technique 
would prove valuable to the analysis of viral preparations, and if it is capable of 
quantifying vector size and aggregation reliably would provide an extremely useful tool 
to the field of gene therapy.  
In most protocols (including the one used in these experiments), virus containing 
supernatant is passed through a 0.45 µM filter, which would block the very large 
aggregates but potentially not smaller clusters from being collected. Some protocols use 
an even smaller pore sized filter (0.22 µM), which would further limit aggregate 
presence. If aggregation is increased over time and it appears that this affects efficacy, 
then it would be logical to utilize a smaller pored filter. It is likely that most of the 
aggregates would be precipitated during the initial centrifugation and filtration steps to 
remove cell debris, seen in all production protocols. This would preclude their impact on 
infectivity beyond lowering viral titer.  
An additional way pH can impact vectors is by “priming” VSVG for fusion. The 
priming can allow increased fusion at the cell surface, instead of internally via the 
endocytic/low-pH endosome pathway. This would correspond with our results showing 
that pretreatment of vector with low pH media at room temperature can increase lentiviral 
vector transduction efficiency in vitro. And conceptually, this increased surface entry 
may be doubly beneficial, as it coincides with HIV-1’s normal site of capsid release and 
potentially cofactors it requires to mediate the maximally productive transduction of 
cells. The “priming” may then allow for more ease in transducing otherwise difficult to 
transduce cell populations.   
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To determine if vector can be “primed” for increased transduction efficiency, a 
single batch of virus could be incubated in media of different pHs and its transduction 
efficiency tested on multiple cell types in an extension of the experiments shown in 
Figure 2-2. In conjunction with their experiments Hirai et al treated virus with HCl to 
lower the pH to 7.0, which did increase their glial-tropism. However, this “priming” 
phenomenon seen may be separate from the changes in transduction due to harvest 
conditions. While we do see a trend towards the transduction of neurons in vivo, the 
correlation between harvesting at lower pHs and improved transduction is true only under 
certain circumstances. And when looking at transduction efficiency in vitro, there was no 
correlation between harvest pH and percent transduction. In all but one cell lines tested 
the 293T produced 40 hr harvest (pH = 7) performed best. Taken together, this would 
indicate that any direct effects of pH are transitory in nature and long-term exposure to 
low pH does not have the same outcome.  
Lentiviral vectors are not stable at 37° C for extended periods of time (T1/2 = 10 
hrs) making the effects of prolonged exposure to different pHs difficult to address. 
Lentivectors are considerably more stable at 4° C, but would not replicate the conditions 
of vector production. It has already been published that the half-life of VSVG 
pseudotyped lentivirus is decreased by over 80% (compared to pH = 7.0) when the vector 
is incubated at pH = 6.0 (at 37° C), indicating prolonged exposure to subneutral pH at 
physiological temperatures is detrimental to vector functionality.  
Despite being the most obvious change occurring when comparing harvest 
lengths, pH is not the only change taking place and it may have only an indirect effect or 
no effect at all. It has been proposed that low pH results in an up-regulation (and/or 
 77	  
increased activity) of cellular proteases, which in turn cleave VSVG and alter vector 
functionality. Proteases of both viral and cellular origin are known to be involved in the 
maturation process of many viruses. Expression patterns of these cellular proteases have 
long been known to affect the tissue tropism and virulence of viruses (Reviewed in [213, 
214]). Furin and other endoproteases are required for cleavage of HIV-1’s GP160 into its 
functional form of GP120 and GP41 (reviewed in [215]), cathepsin L is involved in the 
processing of hendra virus [216] and influenza HA and Sendai F proteins all require cell 
proteases to become fully functional, to name a few. Unlike these glycoproteins, VSVG 
does not undergo extensive proteolytic modification during its maturation process. 
However, VSVG has been observed to be cleaved into a soluble form (consisting of the 
extracellular domain) and a membrane bound form (consisting of 22 amino acids of the 
ectodomain, the transmembrane domain and the cytoplasmic tail) that can be 
incorporated into virus [217]. This digest is thought to occur in the endoplasmic 
reticulum, and interestingly the amount of soluble VSVG produced can be influenced by 
pH [218]. Crimmins et al [219] showed that digestion of VSVG with the aspartyl 
protease Cathepsin D gave a similar digestion pattern, but the native enzymatic basis for 
creation of soluble VSVG has not been determined. When VSVG pseudotyped lentivirus 
is produced without serum in the presence of various protease inhibitors (with a specific 
inhibitor of cathepsin K performing best) the preference for Purkinje cells is increased. It 
is additionally indicated that cathepsin K is expressed by the 293T cells used to produce 
the vector and digestion of VSVG does occur, though this data is not shown [220].  
The first experiment to be done would be to confirm that VSVG is being digested 
in 293T and 293FT cells, and if it is expressed, determine if there is a difference in its 
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digestion pattern at the appropriate harvest lengths. In other studies, we have seen 
banding patterns on western blots that may indicate cleavage of VSVG (Control Lanes 
Figure 3-4 and 3-5). These bands were detected using an antibody to the cytoplasmic tail 
of VSVG and therefore only products containing the c-terminus can be visualized (a band 
of approximately10 kDa is seen). To determine if VSVG is being cleaved over time, 
plasmid DNA encoding VSVG would need to transiently transfected into both producer 
cell lines and supernatant, cell lysates and cell surface protein collected at 40 and 64 hrs 
post-transfection. All three of these fractions would need to be harvested in order to 
assess if soluble VSVG is being produced and if truncated membrane bound form is 
being trafficked to the cell surface. It will also allow the determination of whether or not 
other cleavage products are being produced. Blots would need to be probed with 
antibodies to both the cytoplasmic domain and the ectodomain in order to visualize both 
main cleavage products.  Based on our observations and the altered infectivity seen when 
VSVG pseudotyped lentivirus is produced in the presence of protease inhibitors, it would 
be expected that some digestion is taking place and the products of this are available for 
incorporation into virions. The expectation for how this pattern of digestion may change 
when comparing harvest lengths and how the digestion impacts tropism is unclear. 
Though it may be expected that vectors with higher overall transduction efficiencies 
would have more full length VSVG available to them.  
If digestion of VSVG is seen in the previous experiment, the next step would be 
to determine which protease(s) are leading to this cleavage. As mentioned, the protease 
underlying the physiological formation of soluble VSVG is still not known. Neither is 
whether the increase in neurotropism is due to the protease inhibitors preventing cleavage 
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of VSVG or by preventing their action on some other molecule. Those shown to alter 
tropism are the matrix metalloproteinase inhibitors CGS-27023A and Timp1, cathepsin 
inhibitor I and unspecified inhibitors of cathepsin K and cysteine/serine proteases. To 
perform a screen for the specific protease that is cleaving VSVG, at a minimum the 
following molecules should be tested: CGS-27023A, Timp1, cathepsin inhibitor I and III, 
Pepstatin A, Leupeptin, E64d, CA-074Me and at least one specific cathepsin K inhibitor 
(I-III). Many of these compounds have been studied in relationship to viral infection of 
cells [221-223], but not during the production of vector. If a likely protease (or proteases) 
appears to digest VSVG, then that molecule should be targeted to see whether its activity 
is altered in different harvest lengths and producer cell lines. Many kits exist to assay the 
activity of specific proteases, and cell lysates could be screened for activity. Most 
cathepsins are lysosomal enzymes and consequently more active at lower pH ranges. As a 
result, lowered culture media pH may cause inappropriate activation of these enzymes, 
though this would run counter to Chen et al’s observation of increased soluble VSVG 
production at higher pH’s.  
While degradation of VSVG would appear to be a likely mechanism for changes 
in vector transduction, it is possible that the two events are unrelated. If no degradation is 
seen or if the degradation does not change significantly with different conditions then 
VSVG may not be involved in the changes in transduction. In this situation, cell lysates 
should still be assayed for changes in activity of cathepsin’s (specifically K) and 
cysteine/serine proteases, under vector production conditions. Taking into account the 
reports of Torashima et al, it would be expected that a cathepsin family member or 
cysteine/serine protease would have altered activity during virus production as their 
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inhibitors significantly increase neuronal tropism. Matrix metalloproteinases have been 
shown to help activate the precursors of cathepsins (and vice versa), which may explain 
the broad effectiveness of protease inhibitors seen. It also may foreshadow the 
effectiveness of multiple inhibitors in preventing VSVG digestion. The substrate 
mediating this effect is less clear and could be any number of viral or cellular proteins, 
and if not VSVG would require an extensive screening process to discover.  
Based on our results, differences in transduction appeared more significant when 
comparing cell lines then with harvest length. This would suggest that some difference 
between 293T and 293FT cells is mediating the transduction difference. These results 
could be due to proteases, as discussed in the proceeding paragraphs, or there could be a 
wide range of potential producer cell factors influencing the infectivity of the vectors. 
Some of these factors will be proposed here, however experiment designs to assay them 
will not be discussed in detail.  
Enveloped viruses are known to incorporate a large number of host cell proteins 
(reviewed in [224], and recently explored by [225]). Some of these proteins are thought 
to have a functional reason for their presence, either as part of the viral maturation 
process (p54NRB – a RNA binding protein) or as potentially important factors for 
infectivity (CypA). Given the large numbers of cellular proteins incorporated into 
lentiviral vectors (~100), it is conceivable that a number of them could influence vector 
efficacy. One example of this is CypA, of which upwards of 200 copies can included in a 
single HIV1 virion. Studies of its significance point to roles in maturation [226, 227], cell 
binding [228] and post-entry events [229]. CypA expression levels correlate with wild-
type HIV1 infectivity [230], increasing the rate at which reverse transcriptase becomes 
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maximally active [231]. Another example is APOBEC3G/CEM15, a component of the 
machinery responsible for cellular RNA editing. Interaction of the molecule with the viral 
genome converts cytodine to uracil, potentially inducing detrimental mutations that may 
alter viral transgene expression. In intact HIV1, vif may act to bind APOBEC3G and 
prevent this from occurring [232-234]. With current generation lentivectors not including 
vif (and the other accessory genes), they may be more sensitive to changes in expression 
of certain cellular factors. Expression levels of both of these proteins in each cell line, 
under harvest conditions, may provide interesting information that can be related to the 
vector infectivity. Incorporation levels in the virions would also be enlightening. 
Additional cellular factors have been shown to influence infectivity, such as 
cholesterol content [151, 152] and chondroitin sulfate proteoglycans (CSPGs) in the viral 
supernatant [153]. It has been shown previously that cellular components and serum 
[154] can be present in lentiviral vector preparations and lead to an immune response and 
poorer transduction efficiency in transduced animals. Moreover, highly purified lentiviral 
vector preparations, or vector produced in the absence of serum do appear to have a 
higher effective titer [155]. As the longer harvest times had lower transduction 
efficiencies in vitro, it is possible that as the cells stay in culture longer during the 
production cycle, some factor with a negative impact on viral efficacy builds up resulting 
in reduced lentiviral vector quality. In fact, this has been shown in the production of 
adenoviral vectors where increased cell densities (as would be seen at longer lentiviral 
harvest time-points due to continued division of the producer cells) actually result in 
lower viral efficacy [156]. This is by no means an exhaustive list, and any of these factors 
(or others) may be influencing vector transduction capabilities.  
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Harvest media serum has also been implicated in altering tropism, where different 
lot’s and sources of fetal bovine serum (FBS) can result in altered transduction (vector 
produced under otherwise identical conditions) [120]. Production under a wide range of 
serums can result in altered infectivity [235], and generally this appears to be related to 
susceptibility to serum complement. In these studies virus was produced only in newborn 
calf serum (NCS) of a single lot, which would preclude it from directly causing 
transduction changes. However, NCS likely has different components then FBS does and 
this could be a potential reason for difference in transduction patterns seen at different 
pHs.  
Based on the number of potential factors affecting vector transduction listed in 
this relatively short review of the subject, it can be seen that there is a potential for a 
significant amount of research in this area. The studies outlined here looked at the effects 
of both pH and harvest cell line on vector efficacy. pH did not have the same affects as 
previously reported, though there was a distinct difference with harvest cell lines. These 
results indicate that effects on tropism and efficacy may not be as clear cut as previously 
thought, and that further research needs to be done in order to properly tailor production 
protocols to maximize tropism and efficacy. 
 
Novel chimeras to specifically target lentiviral vectors  
 The second technique employed in this dissertation to influence the targeting of 
lentiviral vectors was the creation of novel chimeric pseudotypes. The ability of lentiviral 
vectors to incorporate heterologous glycoproteins has increased their utility considerably. 
This expanded utility is constrained by the natural tropisms of the viral proteins, and may 
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not sufficiently focus in all systems. To remedy this researchers have begun developing 
chimeric viral surface proteins with the goal of improving the targeting of vectors such 
that therapeutic genes can be delivered to very define subpopulations of cells. The studies 
in chapter three describe the creation of a novel chimera between NGF and VSVG, with 
the goal of utilizing it to target lentiviral vectors to nociceptive sensory neurons. While 
these studies were not successful in improving targeting, they do provide important 
information about what modifications can and cannot be made to VSVG.  
 Initially this section will discuss the expected results for the NGF-VSVG 
chimeras and outline the experimental plan had this strategy been successful. Several 
alternate strategies will be addressed, including adaptations to other vector systems. As 
discussed, the goal of the studies in chapter three were to generate a pseudotype that 
constrained lentiviral transduction to nociceptive neurons. NGF binds with a very high 
affinity to its receptor, TrkA, which is primarily expressed on the nociceptive sensory 
fibers of the dorsal root ganglia. It was thought that the transmembrane and cytoplasmic 
domains of VSVG would be able to act as a membrane anchor for NGF, while at the 
same time increasing the probability of lentiviral incorportation (over related strategies 
which use a non-viral membrane protein anchor [236] 
 If one of the NGF-VSVG chimeras had folded properly, it would be expected that 
it be trafficked from the endoplasmic reticulum to the golgi and on to the cell surface. 
The cell surface expression would be detected by selective biotinylation of membrane 
proteins and visualization via western blot. Presence of the protein at the cell surface does 
not guarantee that the protein is in a proper conformation or oligomeric status to bind to 
the TrkA receptor. Determining this is relatively straightforward conceptually, though the 
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creation of a new cellular localization for NGF results in a lack of readily available 
positive controls. The main receptor for NGF is commercially available as a soluble 
protein (TrkA-fc), which can be used to label cells expressing NGF-VSVG in the same 
manner as an antibody could. Successful TrkA-fc immunostaining would indicate that 
NGF is being displayed on the cell surface in a form permissive to binding of the TrkA 
receptor. Lack of staining with TrkA-fc would not preclude the fact that the chimera is 
folded properly, unless some form of immobilized NGF could be tested as well. 
Conformation and non-conformation specific NGF antibodies would also need to be 
tested for immunostaining of the chimera (though the conformation specific antibody 
would suffer from the same lack of positive control as TrkA-fc).  
 Upon establishing surface expression and ability to bind receptor, the next step 
would be to produce lentivirus bearing this pseudotype. Vector would first be tested in 
vitro on cells known to be responsive to NGF and/or express the TrkA receptor. Rat 
pheochromocytoma (PC12) cells are NGF responsive, and NGF displaying vectors would 
be expected to transduce these cells at significantly higher level then wild-type VSVG or 
fusogne glycoprotein alone pseudotyped vector. In addition to PC12 cells, the NGF-
VSVG pseudotype should be tested on primary dorsal root ganglion (DRG) cultures. 
Testing transduction on dorsal root ganglion cultures more closely resembles the 
conditions that vector would encounter in vivo and includes non-neuronal cells and 
neurons that do not express TrkA. Transfected cultures could then be fixed and stained to 
determine which populations of cells are being transduced. GFP expression would be 
colocalized with immunostaining for TrkA, calcitonin gene-related peptide (CGRP- 
nociceptors) and parvalbumin (proprioceptors). Based on what is known about TrkA 
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expression it would be expected that the vast majority (if not all) of the GFP positive cells 
would also be CGRP positive, indicating they are nociceptive sensory neurons. It is 
conceivable that the transduction will not be exclusive to CGRP positive cells however. 
This could be due to unexpected/non-specific interactions mediated by NGF-VSVG as 
well as due to the co-expressed fusogenic glycoprotein. The fusogenic glycoprotein 
(HAtmt) is a viral glycoprotein that has had its receptor binding sites mutated, but 
receptor binding cannot be completely abolished while maintaining fusogenic capacity 
[199]. Whether there is transduction of CGRP negative cells or not, it is important to 
compare NGF-VSVG/HAtmt lentivirus transduction patterns to vectors pseudotyped with 
only NGF-VSVG (should be zero transduction) or HAtmt (should be almost zero 
transduction). This will allow determination of the contribution of HAtmt and NGF-
VSVG to the overall tropism.  
 Following successful in vitro targeting, the next step would be to determine if this 
targeting specifity was maintained in vivo. The therapeutic goal of this project was to 
generate a pseudotyped that could be used in the gene therapy of chronic pain type 
conditions. It would be expected that transduction patterns would be faithfully replicated 
in vitro, however that is not always true.  Lentiviral vectors pseudotyped with NGF-
VSVG/HAtmt and each surface protein separately would be injected into the superficial 
laminae of the spinal cord or directly into the DRG. Injection of the NGF-VSVG/HAtmt 
pseudotyped vector would be expected to primarily transduce fibers that immunostain 
with CGRP and TrkA.  
 The chimeric glycoproteins produced as part of the research for this dissertation 
appear to be entirely retained in the endoplasmic reticulum, indicating that there is a 
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problem with the vectors design resulting in misfolding. The construct used for one of the 
NGF chimeras and the GDNF chimera has been previously shown to accept the insertion 
of avidin/streptavidin as its extracellular domain and successfully retarget lentiviral 
vectors [193]. This would lead to the conclusion that some characteristic of these 
neurotrophins is incompatible with this system. Based on these results there are different 
options available to achieve the same end result of targeting nociceptive sensory neurons.  
 Despite being a highly studied viral protein and a model system for membrane 
fusion, accounts of VSVG’s use in chimeric targeting have been scarce [193, 196]. This 
is likely due to that fact that VSVG’s cellular receptor has not been identified [237] and 
that its crystal structure only recently determined [238-240]. Without this information it 
is difficult to identify surface exposed and receptor binding domains, which are often the 
target sites utilized to create chimeras. To this point in time, three different successful 
schemes for utilizing VSVG to create targeting chimeras have been published (Fig. 4-2): 
1). Replacement of the ectodomain with avidin/streptavidin [193, 194], 2). Insertion of a 
large targeting molecule at the n-terminus [195] and 3). Insertion of short targeting 
sequences at the n-terminus [196, 197].  
 Surprisingly, when a large 200 amino acid targeting molecule (scFV to MHC I) 
was inserted n-terminally into a VSVG a significant deficit in folding was not seen and 
sufficient protein produced to make functional virus [195]. Functional titer was decreased 
with this strategy though, and this was attributed to the inability of the protein to 
effectively induce membrane fusion. Mature NGF is 120 amino acids, so it would be 
expected that VSVG could tolerate an insertion of this size n-terminally. As shown in 
chapter three of this dissertation, the folding ability of a chimeric protein can be difficult 
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to predict and is not a trivial impediment to success. Inclusion of full length NGF may 
provide an additional challenge to successful protein production when attached to some 
viral glycoproteins. NGF (and the rest of the neurotrophin family) functions as a dimer 
[169], while in order to complete trafficking out of the endoplasmic reticulum VSVG 
must form trimers [241]. These competitive interests may lead to the retention of the 
chimeras in the endoplasmic reticulum (one of the likely causes for the failure of these 
studies).  
 In several sources, loop 2 of NGF (Figure 3-1) has been shown to be sufficient to 
bind and activate TrkA [171-174]. A short peptide coinciding with this loop could be 
inserted n-terminally in a manner similar to the collagen binding domain as outlined by 
Guibinga et al [196]. In their studies, even though the insertion consisted of only ten 
amino acids, folding was significantly impaired and surface expression of the protein 
required incubation of cells at lower temperatures. This is in direct opposition to the 
apparent ease by which the larger (200 amino acid) insertion folded, and illustrates the 
somewhat confounding outcomes seen. Insertion of any peptide into VSVG would likely 
serve to destabilize the native folding process and lower temperatures may or may not 
rescue its folding and expression. Yu et al performed random insertions of hexahistidines, 
many of which exhibited folding deficits, though the n-terminal insertion gave the vector 
titer closest to that seen with wild-type VSVG. Of these two direct insertion options for 
creating NGF-VSVG chimeras, this may be the more promising. It consists of a 
theoretically less invasive disruption and will not encounter competing dimerization 
versus trimerization forces in the endoplasmic reticulum.  
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 The strategy utilized in this dissertation as well as in the two alternate proposals 
listed so far all rely on some portion of NGF folding into its native structure and being 
able to bind TrkA, while being part of another protein. Additional methods of targeting 
enveloped vectors utilize direct incorporation of antibodies to cell surface markers or 
through binding domains and post-production transient interaction with the targeting 
molecule.  
 As mentioned, the construct used to create some of the chimeras in this 
dissertation was originally designed with avidin in place of VSVG’s ectodomain. This 
method allows the production of virus, and then the post-production binding of a 
biotinylated targeting molecule (in their report they explored multiple targeting 
molecules). To achieve nociceptive sensory neuron targeting with this system, purified 
NGF would need to be biotinylated and then incubated with virus pseudotyped with the 
streptavidin-VSVGED glycoprotein. The targeted, pseudotyped vector could then be used 
to specifically transduce cells. This targeting system allows for flexible targeting, 
meaning large quantities of untargeted vector can be produced and then targeted as 
needed immediately prior to use. It also allows higher throughput screening of targeting 
molecules, as individual batches of virus do not need to be produced to test each 
molecule. Each streptavidin-VSVGED molecule has the ability to bind four biotinylated-
NGFs, potentially eliminating problems associated NGF dimerization and also increasing 
the potency of targeting. Similarly, a biotinylated antibody to TrkA (or some other 
surface molecule) could be used in place of NGF to achieve the same targeting profile. 
Many biotinylated antibodies are commercially available making screening different 
targeting profiles simpler. In a related system, the sindbis virus glycoprotein has had its 
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receptor binding domain replaced with the antibody binding domain of protein A [242] 
and it has been used in several studies [198, 243]. 
 Though Dreja et al saw efficient protein production following direct fusion of α-
MHC I scfv to the n-terminal end of VSVG, the potential for misfolding and non-
function is much higher than with transient binding of an antibody. Regardless, it is an 
additional option available for creating novel targeting molecules and one that has been 
successful using the MLV retroviral glycoprotein.  
 Validation of all the strategies outlined above would follow very similar 
experimental paths. Creation of a chimeric glycoprotein requires detection of surface 
expression followed by determining its ability to bind to the cellular target (in the case of 
an avidin-biotin system, both binding of the targeting molecule and cellular target would 
need to be demonstrated). Vector’s expressing the novel targeting molecule would then 
need to be tested for improved targeting of the tissue or cellular population intended.  
 These studies failed to create a viable targeting molecule for lentiviral vectors; 
however they have shown a specific limitation of using VSVG as a base for creating 
chimeric glycoproteins. Due to some characteristic of their folding of oligomerization, 
NGF and GDNF are not compatible with this system. There are several other mechanisms 
for achieving the goal of specific targeting of nociceptive sensory neurons, and these 
results would indicate further research in this arena may be more successful utilizing 
some of these other approaches.  
The overall goal of the research outlined in the dissertation was to add to the 
knowledge base associated with the targeting of lentiviral vectors. Specifically, these 
studies looked at how production protocols affect the targeting and efficacy of lentiviral 
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vectors, both in vitro and in vivo. They also assessed whether novel chimeras between 
nerve growth factor and the vesicular stomatitis virus glycoprotein could be used to 
pseudotype and target lentiviral vectors. Neither method was wholly successful in 
altering lentiviral tropism, however both provided interesting information that may 
ultimately lead to more successful strategies. In the area of lentiviral production, the 
changes in conditions need to be further scrutinized to determine the factor ultimately 
responsible for the changes in transduction, at which point tailoring production protocols 
for specific cellular targets may be feasible. NGF chimeras were non-functional as 
designed in these studies, however other options exist for targeting the intended cell 
populations and may yet prove successful. 
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Glossary 
 
List of Terms 
1. VSV-G: The surface glycoprotein (that mediates receptor binding, and viral 
internalization) of the Vesicular Stomatitis virus. 
2. SV40: Simian virus 40 is a non-enveloped DNA virus of the family 
Polyomaviridae. Early gene transfer vector, and its large T antigen is used to 
immortalize some cell lines.  
3. Spumaretrovirinae: Subfamily of retroviruses characterized by the Simian Foamy 
virus. Complex retroviruses, have been used to make gene therapy vectors. 
4. Orthoretrovirinae: Main subfamily of retroviruses, includes most of the well 
known retroviruses (including HIV).  
5. Gammretroviridae: Genus of retroviruses, which includes MLV and GALV.  
6. Endogeneous Retrovirus: Inheritable genetic sequences within vertebrates thought 
to be the remnants of ancient viral infection of germ cells. Generally do not result 
in gene transcription, except during pregnancy and a few other instances, 
potentially resulting in pathology.  
7. ASLV: Avian Sarcoma Leukosis virus is an endogeneous alpharetrovirus. 
8. RSV: Rous Sarcoma virus is an oncogenic alpharetrovirus.  
9. Amphtropic vs. Ecotropic: Amphotropic viruses have a wide host range and can 
potentially infect multiple species or cell lines. Ecotropic viruses have only a 
narrow host range. When referring to MLV, ecotropic viruses are mouse specific.  
10.  Provirus: Viral genome, which has been integrated into the host cell genome.  
11. MLV: Murine Leukemia viruses are gammaretroviruses, which can be exogenous 
or endogeneous. Used widely in gene therapy and cancer research.  
12. HTLV: Human T-cell Leukemia virus is a complex retrovirus of the deltavirus 
genus.  
13. RD114: An endogeneous retrovirus that infects cats. Its glycoprotein is sometimes 
used as a gene therapy pseudotype.  
14. Rabies virus: A naturally neurotropic member of the Rhabdoviridae family. 
15. Mokola virus: A neurotropic member of the Rhabodoviridae family.  
16. LCMV: Lymphocytic Choriomenigitis virus is an arenavirus, which can cause 
encephalitis and meningitis in humans.  
17. RRV: Ross River virus is a mosquito borne alphavirus.   
18. Sindbis virus: A mosquito borne alphavirus, whose major glycoprotein has three 
components –lending itself well to modification for vector targeting.  
19. HAtmt: A receptor binding deficient form of the FPV Hemagglutinin. 
20. Baculovirus GP64: Major glycoprotein of the insect baculovirus. 
21. p54NRB : RNA binding protein that is involved in transcription/splicing. 
22. CypA: CyclophillinA is a peptidyl-prolyl cis-trans isomerase and aids in protein 
folding. Cyclosporin A binds to it, and may be how the drug mediates 
immunsuppression 
23. APOBEC3G/CEM15: An activation induced cytodine-deaminase, which may 
play a role in antiviral immunity. 
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